

IL. This preprint reports new research that has not been certified by peer review and should not be used to guide chincar practice. 22 German Center Forman Center for Infection Research that has not been certified by peer review and should not be use
NOTE: This preprint reports new research that has not been certified by peer review and should not be u **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

11

- ¹²Paediatric Gastroenterology and Hepatology, University Children's Hospital Tübingen, Tübingen,
-
- ¹³German Center for Infection Research (DZIF), Partner Site Tübingen, Germany
- ¹²Paediatric Gastroenterology and Hepatology, University Children's Hospital Tübingen, Tübingen,
24 Germany
¹³German Center for Infection Research (DZIF), Partner Site Tübingen, Germany
¹⁴Klinik für Allgemeine-, Visz 17
- 25 ¹³German
25 ¹³German
26 ¹⁴Klinik fü
- 26 ¹⁴Klinik für Allgemeine-, Viszeral-, und Transplantationschirurgie, Klinikum der I
27 Munich, Germany
¹⁵Department of Nephrology, Technical University of Munich, Munich, Germany 28 ¹⁵Department of N
29 ¹⁶Department of I
30 Hamburg-Eppendo ¹⁵Department of Nephrology, Technical University of Munich, Munich, Germany
- 27 Munich, Germany
28 ¹⁵Department of Nephrology, Technical University of Munich, Munich, Germany
¹⁶Department of Pediatric Nephrology, University Children's Hospital, University Medical Center ¹⁶Department of Pediatric Nephrology, University Children's Hospital, University Chinamburg-Eppendorf, Hamburg, Germany
31 ¹⁷Department of Nephrology and Medical Intensive Care, Charité – Universitätsn ¹⁶Department of Pediatric Nephrology, University Children's Hospital, University Medical Center
-
- 20 Department of Penantic Nephrology, University Children's Enterprise, Children's Hospital, University Medical
30 Hamburg-Eppendorf, Hamburg, Germany
31 ¹⁷Department of Nephrology and Medical Intensive Care, Charité U 131 Hamburg-Eppendorf, Hamburg, Germany
31 Happendorf, Hamburg, Germany
32 Germany
33 *shared contribution $\ddot{}$
-
-
- 32 Germany
33 *shared contribution
34 *shared last authorship 22 Framany
33 *shared c
34 #shared la
35 34 [#]shared last authorshi
35
36 Correspondence to: "shared last authorship
-
- 35
36 Correspondence to:
37 Johannes Holle, MD
-
- --
36
37
38 137 Johannes Holle, MD
38 Experimental and Cli
39 Charité – Universität 28 Experimental and Cli
39 Charité – Universität
40 Lindenberger Weg 8
- 29 Charité Universitätsmedizin Berlin
20 Lindenberger Weg 80
21 13125 Berlin
- 39 Charles Universitätsmedian
19 Charles Universität
19 Charlie
19 Charles Universität
19 Charles Universität
19 Charles Universität
19 Charles Universität
19 Charles Universität
19 Charles Universität
-
-
- 11 Lindenberger Weg 80
41 Lindenberger 13125
43 Mail: <u>johannes-benjan</u> 42 Germany
43 Mail: <u>johanne</u>
13 43 Mail: <u>joha</u>
43 Mail: <u>joha</u> 43 Mail: johannes-benjamin.holle.de
13 Mai – Johannes Benjamin.holle.de
13 Mai – Johannes Benjamin.holle.de

44 Abstract
45 <u>Backgrour</u>
47 in modul graft survival critically affected by the recipient's immune response. The role of the gut microbiome
at in modulating this immune response remains underexplored. Our study investigates how
microbiome alterations might ass graft survival critically affected by the recipient's immune response. The role of the gut microbiome

in modulating this immune response remains underexplored. Our study investigates how

microbiome alterations might asso

modulation alterations might associate with allograft rejection.

47 **Methods:** We analyzed existing biomaterials of a multicenter prospective study involving 217 KT

49 **Methods:** We analyzed existing biomaterials of a mu Methods: We analyzed existing biomaterials of a multicenter
150 microbiome were analyzed using 165 rRNA gene amplicon served to the microbiome were analyzed using 165 rRNA gene amplicon served to the production. Fig. 23

49 Methods: Theorem in the German Center for Infection Research. Changes in the gut

19 Methods: Microbiome were analyzed using 16S rRNA gene amplicon sequencing and functional predictions

19 Methods: Propensity 51 microbiome were analyzed using 16S rRNA gene amplicon sequencing and functional predictions
52 (PICRUSt2) and quantitative PCRs for the production potential of propionate and butyrate.
53 Propensity score matching was u 52 (PICRUSt2) and quantitative PCRs for the production potential of propionate and butyrate.
53 Propensity score matching was utilized to compare patients who experienced graft rejection with
54 those who did not.
55 Besul Fig. 2)
53 Propensity score matching was utilized to compare patients who experienced graft rejection with
54 those who did not.
55 <u>Results:</u> The gut microbiome showed gradual recovery post-KT, marked by an increase of Sh

54 those who did not.
53 <u>Results:</u> The gut microbiome showed gradual recovery post-KT, marked by an increase of Shannon
56 diversity and SCFA-producing bacterial taxa. However, prior to graft rejection, significant altera 55 Results: The gut minimals:
56 diversity and SCFA-
57 were noted in microsoft 55 diversity and SCFA-producing bacterial taxa. However, prior to graft rejection, significant alterations
57 were noted in microbiome composition, characterized by a decrease in microbial diversity and SCFA-
58 producing 57 were noted in microbiome composition, characterized by a decrease in microbial diversity and SCFA-
58 producing taxa. Post-rejection analysis revealed normalization of these microbiome features.
59 Functional analysis h 61 patients demonstrated a partial overlap of the microbiome alterations preceding graft rejection with 59 Functional analysis highlighted a decreased potential for SCFA production in patients prior to
60 rejection. Comparison to published microbiome signatures from chronic kidney disease (CKD)
61 patients demonstrated a par 59 Functional and the microbiome signatures from chronic kidney disease (CKD)
51 patients demonstrated a partial overlap of the microbiome alterations preceding graft rejection with
52 Conclusions: Our findings suggest tha For the published microbiome signature from chronic manner manner (CMD)
for the alterations typically found in CKD.
<u>Conclusions:</u> Our findings suggest that alterations in the gut microbiome composition and function
for us

the alterations typically found in CKD.

63 <u>Conclusions:</u> Our findings suggest that alterations in the gut microbiome composition and function

64 may precede and influence KT rejection, suggesting potential for use as bi Conclusions: Our findings suggest that
64 may precede and influence KT rejet
65 therapeutic microbiome-targeting inte may precede and influence KT rejection, suggesting potential for use as biomarker and early
therapeutic microbiome-targeting interventions to improve transplant outcomes.
66 $\frac{1}{2}$ therapeutic microbiome-targeting interventions to improve transplant outcomes.
66 65 therapeutic microbiome-targeting interventions to improve transplant outcomes.

75 1. Introduction
76 Kidney transplanta
77 failure (CKD G5)¹
78 comorbidities, suc Francey CKD G5)¹. Despite ongoing efforts to prevent the progression of CKD and related
comorbidities, successful KT and graft survival, especially prevention of graft rejection, are of
outmost importance. Graft rejectio failure (CKD G5)². Despite ongoing efforts to prevent the progression of CKD and related
comorbidities, successful KT and graft survival, especially prevention of graft rejection, are of
outmost importance. Graft rejecti 28 comorbidities, successful Channel Graft survival, prevention of graft rejection, and the position of graft and subsequently recipient survival². Whether a patient experiences acute or chronic graft rejection or not is 29 on graft and subsequently recipient survival². Whether a patient experiences acute or chronic graft rejection or not is, according to the current scientific understanding, largely dependent on immune mechanisms, the on graft and subsequently recipient survival². Whether a patient experiences acute or chronic graft

81 rejection or not is, according to the current scientific understanding, largely dependent on immune

82 mechanisms,

82 mechanisms, the modifiers of which still remain poorly understood³.
83 Of late, the gut microbiome gained considerable attention as key modulator of the immune system
84 in both healthy and disease conditions⁴. Micr mechanisms, the modifiers of which still remain poorly understood".

Of late, the gut microbiome gained considerable attention as key m

in both healthy and disease conditions⁴. Microbiota, their metabc

interact with nu 84 in both healthy and disease conditions⁴. Microbiota, their metabolites and associated molecules
85 interact with numerous host organs including mucosa-associated and systemic immune cells and
86 thereby shape host imm in both healthy and disease conditions". Microbiota, their metabolites and associated molecules
interact with numerous host organs including mucosa-associated and systemic immune cells and
thereby shape host immunity and i 86 thereby shape host immunity and inflammation⁵. Patients with CKD exhibit marked alterations to
87 their gut microbiome composition and subsequent dysregulation of metabolite abundance⁶. In
88 particular, a switch fr thereby shape host immunity and inflammation". Patients with CKD exhibit marked alterations to
their gut microbiome composition and subsequent dysregulation of metabolite abundance⁶. In
particular, a switch from saccharo their gut microbiome composition and subsequent dysregulation of metabolite abundance". In
particular, a switch from saccharolytic to proteolytic fermentation is observed⁷. On one hand this
leads to lower intestinal and particular, a switch from saccharolytic to proteolytic fermentation is observed'. On one hand this
leads to lower intestinal and systemic concentrations of short-chain fatty acids (SCFA)⁸, previously
identified as induce leads to lower intestinal and systemic concentrations of short-chain fatty acids (SCFA)°, previously
90 identified as inducers of regulatory immunity⁹. On the other hand, increased levels of pro-
91 inflammatory metaboli

identified as inducers of regulatory immunity". On the other hand, increased levels of pro-

91 inflammatory metabolites, such as tryptophan-derived indoxyl sulfate, are observed⁸.

92 After KT, CKD-related microbiome al inflammatory metabolites, such as tryptophan-derived indoxyl sulfate, are observed".

After KT, CKD-related microbiome alterations can partially persist, presumably by a

additional factors such as immunosuppression¹⁰, a 93 additional factors such as immunosuppression¹⁰, and are associated with clinical events like post-
94 transplant diarrhea^{11,12}. A recent study rigorously demonstrated an association between lower gut
95 microbial d additional factors such as immunosuppression²⁵, and are associated with clinical events like post-
194 transplant diarrhea^{11,12}. A recent study rigorously demonstrated an association between lower gut
195 microbial div transplant diarrhea²²¹¹². A recent study rigorously demonstrated an association between lower gut
microbial diversity in patients with solid organ transplantation and increased overall mortality¹³. A
growing body of ev microbial diversity in patients with solid organ transplantation and increased overall mortality*³. A
growing body of evidence implicates the gut microbiota in alloimmunity and graft rejection. Germ-
free mice and mice 98 conventional mice, suggesting that alloimmunity is modulated by microbiota¹⁴. Furthermore, recent
99 studies indicate that gut microbes directly affect immune-regulatory cells (regulatory T cells, Th17
5 conventional mice, suggesting that alloimmunity is modulated by microbiota²⁷. Furthermore, recent
studies indicate that gut microbes directly affect immune-regulatory cells (regulatory T cells, Th17
5

96 growing body of evidence implicates the gut microbiota in alloimmunity and graft rejection. Germ-99 studies indicate that gut microbes directly affect immune-regulatory cells (regulatory T cells, Th17

cells)^{15,16}, with SCFA playing a central role in this relationship²⁷. Studies in mice showed that SCFA
101 supplementation mediates donor-specific tolerance to kidney allograft through induction of Foxp3⁺
102 regulat supplementation mediates donor-specific tolerance to kidney allograft through induction of Foxp3¹
102 regulatory T-cells¹⁸. Finally, human interventional studies are underway, aiming to improve CKD-
103 associated micr regulatory T-cells². Finally, human interventional studies are underway, aiming to improve CKD-
103 associated microbiome alterations by prebiotic inulin supplementation¹⁹ or at improving immune
104 regulation by suppl

associated microbiome alterations by prebiotic inulin supplementation⁴⁹ or at improving immune
104 regulation by supplementation of regulatory T cells²⁰.
105 In this study, we analyzed longitudinal changes in the comp regulation by supplementation of regulatory T cells²⁰.
105 . In this study, we analyzed longitudinal changes in
106 . microbiome of KT recipients enrolled in the transplair
107 . Infectious Diseases (DZIF)²¹ and conne 106 Infectione of KT recipients enrolled in the transplant cohort (Tx cohort) of the German Center of
107 Infectious Diseases (DZIF)²¹ and connect them with the clinical outcomes, specifically graft survival
108 Infectio 107 Infectious Diseases (DZIF)²¹ and connect them with the clinical outcomes, specifically graft survival
108 and rejection. In a propensity score-matched subcohort we identify microbial alterations preceding
109 graft r Infectious Diseases (DZIF)²² and connect them with the clinical outcomes, specifically graft survival

108 and rejection. In a propensity score-matched subcohort we identify microbial alterations preceding

109 graft rej 109 and rejections and transplant dysfunction.
108 and rejections and transplant dysfunction. 110

111 2. Materials and methods
112 Study Population and Design
113 All patients analyzed in this s
114 prospective cohort study con 112 Study Population and Design
113 All patients analyzed in this :
114 prospective cohort study con
115 Heidelberg, Munich (Technic 114 prospective cohort study conducted at four German transplant centers (University Hospitals in
115 Heidelberg, Munich (Technical University and Ludwig Maximilian University) and Tübingen)²¹.
116 Together, these center 115 Heidelberg, Munich (Technical University and Ludwig Maximilian University) and Tübingen)²¹.
116 Together, these centers cover over 20% of solid organ transplants in Germany²² providing a
117 representative picture Heidelberg, Munich (Technical University and Ludwig Maximilian University) and Tübingen)¹¹.
116 Together, these centers cover over 20% of solid organ transplants in Germany²² providing a
117 representative picture of p

Together, these centers cover over 20% of solid organ transplants in Germany²² providing a
117 representative picture of post-transplant course in Germany.
118 For the present study, we analyzed data from all kidney allo 118 For the present study, we analyzed data from all kidney
119 participate and received a kidney transplant between July
120 collected between March 2017 and September 2021. Patient participate and received a kidney transplant between July 2014 and July 2021. Samples were
120 collected between March 2017 and September 2021. Patients receiving multi-organ transplantation
121 or patients who underwent p 120 collected between March 2017 and September 2021. Patients receiving multi-organ transplantation
121 or patients who underwent previous solid organ transplantation were excluded (Supplemental
122 Figure 1). Moreover, pa 121 or patients who underwent previous solid organ transplantation were excluded (Supplemental
122 Figure 1). Moreover, participants without fecal samples were excluded from our analysis. Ethics
123 approval was obtained f 122 Figure 1). Moreover, participants without fecal samples were excluded from our analysis. Ethics
123 approval was obtained from all participating centers (Heidelberg #S-585/2013, TU Munich #5926/13,
124 LMU Munich #380-123 approval was obtained from all participating centers (Heidelberg #S-585/2013, TU Munich #5926/13,
124 LMU Munich #380-15, Tübingen #327/2014BO1), and all participants provided written informed
125 consent. The experime 124 LMU Munich #380-15, Tübingen #327/2014BO1), and all participants provided written informed
125 consent. The experimental analysis of fecal samples, including metadata analysis, was approved by
126 the ethics board of C 125 consent. The experimental analysis of fecal samples, including metadata analysis, was approved by
126 the ethics board of Charité – Universitätsmedizin Berlin (EA2/208/21).
127 The study design, including biomaterial c

126 the ethics board of Charité – Universitätsmedizin Berlin (EA2/208/21).
127 The study design, including biomaterial collection, was described previously²¹. Fecal samples were
128 collected using DNA stabilizing buffer 127 The study design, including biomaterial collection, was described pre
128 collected using DNA stabilizing buffer (STRATEC). Study visits were p
129 KT, at months 3, 6, 9, and 12 after KT and when infections or rejectio The study design, including biomaterial collection, was described previously¹¹. Fecal samples were

collected using DNA stabilizing buffer (STRATEC). Study visits were performed immediately before

I29 KT, at months 3, 6 129 KT, at months 3, 6, 9, and 12 after KT and when infections or rejection events were detected. Clinical
130 and laboratory data were collected at each study visit.
131 Standard of care treatment 130 and laboratory data were collected at each study visit.
131 Standard of care treatment
132 The patients received a standard triple-drug combination of immunosuppressants (comprising a

131 Standard of care treatment
132 The patients received a standard triple-drug combin
133 calcineurin inhibitor, mycophenolate (MPA), and cort 131 Standard of care treatment
132 The patients received a sta
133 calcineurin inhibitor, mycop 133 calcineurin inhibitor, mycophenolate (MPA), and corticosteroids), initially frequently together with
133 calcineurin inhibitor, mycophenolate (MPA), and corticosteroids), initially frequently together with
137 $\frac{1}{3}$ 33 calcineurin inhibitor, mycophenolate (MPA), and corticoster $\frac{1}{2}$, initially together with $\frac{1}{2}$

134 135 infectious complications was suggested to be performed according to KDIGO 2009 guidelines²³,
136 including antiviral prophylaxis with valganciclovir for patients at high risk for cytomegalovirus (CMV)
137 infections, infectious complications was suggested to be performed according to KDIGO 2009 guidelines²⁵,
including antiviral prophylaxis with valganciclovir for patients at high risk for cytomegalovirus (CMV)
infections, trimethopri 137 infections, trimethoprim-sulfamethoxazole prophylaxis against *Pneumocystis jirovecii* and urinary
138 tract infections, *Candida* prophylaxis with oral nystatin or amphotericin B.
139 **Matching of rejection/non-reject** 137 Infections, trimethopini-sulfamethoxazole prophylaxis against Pheumocystis jirovechi and urinary
138 Itract infections, *Candida* prophylaxis with oral nystatin or amphotericin B.
140 We conducted our analysis using R

138 tract infections, *candida* prophylaxis with oral nystatin or amphotencin B.
139 **Matching of rejection/non-rejection patients**
140 We conducted our analysis using R (4.3.2), employing Matchlt (4.5.5)²⁴ pac
141 Patie 139 Matching of rejection, non-rejection patients
140 We conducted our analysis using R (4.3.2), em
141 Patients with histologically proven rejection ev
142 Banff category 4) and Borderline (Suspicious) We conducted our analysis using R (4.3.2), employing MatchIt (4.5.5)²⁴ package for sample matching.

141 Patients with histologically proven rejection events were assessed (T cell-mediated rejection (TCMR,

142 Banff ca Banff category 4) and Borderline (Suspicious) for acute TCMR (Banff category 3))²⁵, if the rejection occurred within five years after KT and fecal sampling was obtained before the rejection event (time frame 781 days bef Banff category 4) and Borderline (Suspicious) for acute TCMR (Banff category 3))²⁵, if the rejection
occurred within five years after KT and fecal sampling was obtained before the rejection event (time
frame 781 days bef 144 frame 781 days before the rejection till 3 days after rejection). Patients without sample before
145 rejection and those with-mediated rejection (ABMR) were excluded from the analyses, yielding 33
146 patients with rej 145 rejection and those with-mediated rejection (ABMR) were excluded from the analyses, yielding 33
146 patients with rejection events. Stool samples taken closest before the rejection event were selected
147 for analyses. 146 patients with rejection events. Stool samples taken closest before the rejection event were selected
147 for analyses. Control samples were matched based on the absence of rejection and similar baseline
148 characteris 147 for analyses. Control samples were matched based on the absence of rejection and similar baseline
148 characteristics, using nearest neighbour matching with a 2:1 ratio, matching two controls for each
149 rejection cas 148 characteristics, using nearest neighbour matching with a 2:1 ratio, matching two controls for each
149 rejection case based on the factors primary condition, donor type, time since transplantation, age,
150 and gender. 149 rejection case based on the factors primary condition, donor type, time since transplantation, age,
150 and gender. Of the selected 99 patients, one rejection patient was excluded because of primary graft
151 dysfuncti 150 and gender. Of the selected 99 patients, one rejection patient was excluded because of primary graft
151 dysfunction (patient still required dialysis three months after KT) and six patients without rejection
152 were e 151 dysfunction (patient still required dialysis three months after KT) and six patients without rejection
152 were excluded because of sustained poor kidney function (plasma creatinine > 2.5 mg/dL).
153 Detailed informati

were excluded because of sustained poor kidney function (plasma creatinine > 2.5 mg/dL).

153 Detailed information on clinical data preparation, sample collection and processing, 16S amplicon

154 sequencing, SCFA producti 153 Detailed information on clinical data preparation, sample collection and processing, 16S
154 sequencing, SCFA production gene targeting assay (qPCR) and re-analysis of the CKD datase
155 found in the online only supple 154 sequencing, SCFA production gene targeting assay (qPCR) and re-analysis of the CKD dataset²⁶ can be
155 found in the online only supplemental material.
156 Statistical Analysis sequencing, SCFA production gene targeting assay (qPCR) and re-analysis of the CKD dataset⁴⁶ can be
found in the online only supplemental material.
156 **Statistical Analysis**

156 Statistical Analysis
156 Statistical Analysis 156 Statistical Analysis

157 158 variables were presented as numbers and percentages. All statistical analyses were conducted using
159 R (4.2.3).
160 Analysis of alpha diversity and multivariate analysis: Alpha diversity and multivariate analysis wer

159 R (4.2.3).
160 <u>Analysis of alpha diversity and multivariate analysis:</u> Alpha diversity and multivariate analysis were
161 performed on OTU level on the non-rarefied data. Different metrics for alpha Diversities were 160 Analysis
160 <u>Analysis c</u>
161 performe
162 calculated 161 performed on OTU level on the non-rarefied data. Different metrics for alpha Diversities were
162 calculated using the R-package microbiome (v.1.12.0)²⁷. Differences in alpha Diversity were tested
163 using Wilcoxon 162 calculated using the R-package microbiome (v.1.12.0)²⁷. Differences in alpha Diversity were tested
163 using Wilcoxon rank sum test on a significance level of 0.05. For multivariate analysis, Bray-Curtis
164 indices calculated using the R-package microbiome (v.1.12.0)²⁷. Differences in alpha Diversity were tested
163 using Wilcoxon rank sum test on a significance level of 0.05. For multivariate analysis, Bray-Curtis
164 indices wer 164 indices were obtained using the R-package phyloseq (v.1.34.0)²⁸ and tested via PERMANOVA using
165 adonis2 of the R-package vegan (v.2.6-4)²⁹.
166 <u>Cross-sectional comparison:</u> For the association analysis, the R-p

indices were obtained using the R-package phyloseq (v.1.34.0)²⁰ and tested via PERMANOVA using
165 adonis2 of the R-package vegan (v.2.6-4)²⁹.
166 <u>Cross-sectional comparison:</u> For the association analysis, the R-packa adonis2 of the R-package vegan (v.2.6-4)²⁵.
166 ...<u>Cross-sectional comparison:</u> For the associant
167 ... was used ³⁰. The testing was performed on
168 ... all taxonomic levels with a minimum prevair
169 ... binary va was used³⁰. The testing was performed on the rarefied data (minimum read count 10270 reads) and
all taxonomic levels with a minimum prevalence of 0.1. Wilcoxon rank sum test was performed for
binary variables, Spearman's was used³⁰. The testing was performed on the rarefied data (minimum read count 10270 reads) and
168 all taxonomic levels with a minimum prevalence of 0.1. Wilcoxon rank sum test was performed for
169 binary variables, Sp 169 binary variables, Spearman's correlation for continuous variables, and Kruskal-Wallis test for ordinal
170 variables. The obtained p-values were adjusted using the Benjamini-Hochberg false discovery rate
171 (FDR) corr 170 variables. The obtained p-values were adjusted using the Benjamini-Hochberg false discovery rate
171 (FDR) correction. In total, 65 clinical variables were considered as confounding factors (Supplemental
172 Table 1). 171 (FDR) correction. In total, 65 clinical variables were considered as confounding factors (Supplemental
172 Table 1). An association was considered statistically significant when FDR < 0.1.
173 For individual compariso

172 Table 1). An association was considered statistically significant when FDR < 0.1.

173 For individual comparisons of clinical and qPCR parameters, Mann-Whitney U test was performed

174 and p < 0.05 was considered sta 173 For individual comparisons of clinical and qPCR parameters, Mann-Whitney L
174 and $p < 0.05$ was considered statistically significant.
175 <u>Longitudinal Analysis:</u> For the longitudinal analysis, LongDat $(v.1.1.2)^{31}$

173 For individual comparisons of clinical and qPCR parameters, Mann-Whitney D test was performed

174 and p < 0.05 was considered statistically significant.

175 <u>Longitudinal Analysis:</u> For the longitudinal analysis, Lo 175 <u>Longitudinal Analysis:</u> For the longitudinal analysis,
176 binomial generalized linear mixed models over tir
177 random intercept. The models were built on rarefied
178 by Beniamini-Hochberg procedure. A change in a Longitudinal Analysis: For the longitudinal analysis, LongDat (v.1.1.2)⁹⁴ was used, building negative
176 binomial generalized linear mixed models over time after KT, controlling for sample origin by a
177 random interce random intercept. The models were built on rarefied data with default filtering³¹. FDR was controlled
178 by Benjamini-Hochberg procedure. A change in abundance over time as considered statistically
179 significant when random intercept. The models were built on rarefied data with default filtering³⁴. FDR was controlled
178 by Benjamini-Hochberg procedure. A change in abundance over time as considered statistically
179 significant when

179 significant when FDR < 0.1.
180 biversity parameters during different periods before and after KT were compared using Mann-
181 Whitney U test and p < 0.05 was considered statistically significant. 180 Diversity parameters durin
181 Whitney U test and p < 0.05 181 Whitney D test and p < 0.05 was considered statistically significant.

-
- Functional capacity prediction using Picrust2: $PICRUSt2^{22}$ obtained abundances of the KEGG
183 orthologs (KOs) were z-score scaled and tested for significance with a linear model correcting for age
184 and sex (Benjamini 2184 and sex (Benjamini-Hochberg-corrected FDR < 0.05). All significant KOs were mapped to the corresponding GOmixer modules³³ and tested for group difference using Wilcoxon rank sum test with a significance level of FDR
- 185 corresponding GOmixer modules³³ and tested for group difference using Wilcoxon rank sum test
186 with a significance level of FDR < 0.05 using the online tools of GOmixer.
187
- corresponding GOmixer modules³³ and tested for group difference using Wilcoxon rank sum test
186 with a significance level of FDR < 0.05 using the online tools of GOmixer.
187 187

188 **3. Results**
189 **Gut microbic**
190 We used me
191 consists of n 189 Gut incredicted composition recovers gradually post-kidney transplantation
190 We used medical data and fecal samples from the DZIF Transplant Cohort. T
191 consists of nearly 2400 patients undergoing solid organ trans 191 consists of nearly 2400 patients undergoing solid organ transplantation. Here, we focused on fecal
192 samples from patients undergoing KT (n=562 samples, from n= 245 individuals), including kidney
193 donors (n=28) an samples from patients undergoing KT (n=562 samples, from n= 245 individuals), including kidney

193 donors (n=28) and, if available, pre-transplantation samples (n=26). Baseline characteristics of the

194 cohort can be f 193 donors (n=28) and, if available, pre-transplantation samples (n=26). Baseline characteristics of the
194 cohort can be found in Table 1.
195 We analyzed the microbiome composition using 165 rRNA gene amplicon sequencin

194 cohort can be found in Table 1.
195 We analyzed the microbiome composition using 16S rRNA gene amplicon sequencing. For
196 longitudinal analysis post-KT, samples were grouped according to sampling time, namely 0-3 mon 195 We analyzed the microbiome
196 longitudinal analysis post-KT, sa
197 (n=69), 3-12 months (n=226) 12
198 (Sunnlemental Figure 1) Princi 196 Iongitudinal analysis post-KT, samples were grouped according to sampling time, namely 0-3 months
197 (n=69), 3-12 months (n=226) 12-24 months (n=94), 24-36 (n=66), and over 36 months (n=53) post-KT
198 (Supplemental F 197 (n=69), 3-12 months (n=226) 12-24 months (n=94), 24-36 (n=66), and over 36 months (n=53) post-KT
198 (Supplemental Figure 1). Principal Coordinates Analysis (PCoA) of Bray-Curtis dissimilarity revealed
199 an overall s 197 (n=19), 3-12 months (n=19), 3-12 months (n=19), 24-34 (n=19), and over 10-19) post-to
198 (Supplemental Figure 1). Principal Coordinates Analysis (PCoA) of Bray-Curtis dissimilarity revealed
199 an overall stable micro 199 an overall stable microbiome composition post-KT, while the healthy donors and pre-KT groups
199 differed (Fig 1A). While the detected number of operational taxonomic units (OTU, a proxy for
199 bacterial taxa) was mos 1991 differed (Fig 1A). While the detected number of operational taxonomic units (OTU, a proxy for
1991 bacterial taxa) was mostly stable post-transplantation (Fig 1B), we observed significant shifts in the
1992 alpha dive 201 bacterial taxa) was mostly stable post-transplantation (Fig 1B), we observed significant shifts in the
202 alpha diversity as quantified by Shannon diversity index (Fig 1C). While Shannon diversity decreased
203 before 202 alpha diversity as quantified by Shannon diversity index (Fig 1C). While Shannon diversity decreased
203 before and in the first year after transplantation, it gradually increased again over time post-KT. We
204 observ 203 before and in the first year after transplantation, it gradually increased again over time post-KT. We
204 observed a similar trend for Simpson evenness, although most comparisons were not significant (Fig
205 1D).
206 204 bbserved a similar trend for Simpson evenness, although most comparisons were not significant (Fig
205 1D).
206 We performed longitudinal analysis using LongDat³¹ to identify bacterial taxa regulated over time post-K

205 1D).
206 We performed longitudinal analysis using LongDat³¹ to identify bacterial taxa regulated over time
207 post-KT. Post-transplantation, typical SCFA-producing genera like Coprococcus³⁴, Lachnospiraceae³⁵,
2 י
206 We
207 post
208 *Rose* We performed longitudinal analysis using LongDat²⁴ to identify bacterial taxa regulated over time
207 post-KT. Post-transplantation, typical SCFA-producing genera like *Coprococcus*³⁴, *Lachnospiraceae*³⁵,
208 *Roseb* post-KT. Post-transplantation, typical SCFA-producing genera like Coprococcus²⁰¹, Lachnospiraceae²⁰,
208 Roseburia³⁶, Faecalibacteria³⁷ and Ruminocococcus torques group³⁸ increased significantly over time
209 (Fi Roseburia³⁶, Faecalibacteria³⁷ and Ruminocococcus torques group²⁶ increased significantly over time
209 (Fig 1E), suggesting an improvement of CKD-associated microbiome alterations, specifically the
210 impaired prod 209 (Fig 1E), suggesting an improvement of CKD-associated microbiome alterations, specifically the
210 impaired production of SCFA as one of its hallmarks^{6,8}. Furthermore, we observed a decrease in
211 Streptococcus, wh impaired production of SCFA as one of its hallmarks^{9,8}. Furthermore, we observed a decrease in Streptococcus, which was recently linked with subclinical atherosclerosis³⁹ (Fig 1E). In summary, our Streptococcus, which $\emph{Streptococcus},$ which was recently linked with subclinical atherosclerosis $\emph{30}$ (Fig 1E). In summary, our and streptococcus, which was recently linked with subclinical atherosclerosis $\emph{30}$ (Fig 1E). In summary, our

212

213 physiological state after three years or more post-KT.
214 **Kidney transplant rejection profoundly impacts microbiome composition**
215 Since we observed dynamic microbiome changes over time in KT patients, we aimed to 214 **Kidney transplant rejection profoundly impacts microl**
215 Since we observed dynamic microbiome changes ove
216 how transplant rejection events influence this proces 214 Kidney transplant rejection profoundly impacts incredibilities composition
215 Since we observed dynamic microbiome changes over time in KT patients,
216 how transplant rejection events influence this process and, vice 216 how transplant rejection events influence this process and, vice versa, how microbiome alterations
217 may impact allograft immunity. Therefore, we identified fecal samples (n= 157) from patients (n= 76)
218 with biops 217 how transponses and transplant represent transplant represent and, vice versa, how microbiometric intensity
218 with biopsy-proven rejection events at any timepoint after KT (Table 1). PCoA of Bray-Curtis
219 dissimila 218 with biopsy-proven rejection events at any timepoint after KT (Table 1). PCoA of Bray-Curtis
219 dissimilarity showed a distinct clustering of patients experiencing graft rejection compared to KT
220 patients with no r dissimilarity showed a distinct clustering of patients experiencing graft rejection compared to KT
220 patients with no reported rejection (Fig 1F). While the number of detected OTUs was constant over
221 time (Supplementa patients with no reported rejection (Fig 1F). While the number of detected OTUs was constant over
221 time (Supplemental Figure 2), Shannon diversity and Simpson evenness were reduced during the
222 first year post-transpl 221 time (Supplemental Figure 2), Shannon diversity and Simpson evenness were reduced during the
222 first year post-transplantation in rejection patients (Fig 1G-H), which was co-incident with the
223 allograft rejection. 222 first year post-transplantation in rejection patients (Fig 1G-H), which was co-incident with the
223 allograft rejection. Lastly, we performed univariate analyses on genus level using
224 metadeconfound R^{30} . Corres allograft rejection. Lastly, we performed univariate analyses on genus level using
224 metadeconfound ³⁰. Corresponding to the altered composition in the multivariate analysis, we
225 found a large number of differential metadeconfound ³⁰. Corresponding to the altered composition in the multivariate analysis, we
225 found a large number of differentially abundant genera (Supplemental Figure 3). Interestingly, the
226 majority of observed metadeconfoundR³⁰. Corresponding to the altered composition in the multivariate analysis, we
225 found a large number of differentially abundant genera (Supplemental Figure 3). Interestingly, the
226 majority of observed 226 majority of observed effects related to rejection showed a contrasting trend in correlation with the
227 duration between sampling and kidney transplant rejection event (Fig S3). This correlation indicates
228 either m 227 duration between sampling and kidney transplant rejection event (Fig S3). This correlation indicates
228 either microbiome alteration preceding the rejection event, changes in the microbiome post-
229 rejection, or bot either microbiome alteration preceding the rejection event, changes in the microbiome post-
229 rejection, or both. Of note, our analysis indicates that many effects were confounded by patient age
230 and distance to KT.
2

232 We hypothesize, that these changes might precede transplant rejection, as the alterations associate 229 and distance to KT.
231 Taken together, patients who experience KT rejection have an altered gut microbiome composition.
232 We hypothesize, that these changes might precede transplant rejection, as the alterations ass 231 and Taken together, pat
232 we hypothesize, th
233 with the time betwe 232 We hypothesize, that these changes might precede transplant rejection, as the alterations associate
233 with the time between sampling and KT rejection event.
234 Microbiome alterations precede kidney transplant reject 232 We with the time between sampling and KT rejection event.
233 With the time between sampling and KT rejection event.
234 Microbiome alterations precede kidney transplant rejection

234 Microbiome alterations precede kidney transplant rejection exercises 234 Microbiome alterations precede kidney transplant rejection

235 236 KT of rejection and non-rejection patients and to further understand which alterations to the
237 microbiome precede KT rejection, we performed propensity score matching of patients with
238 available fecal samples bef microbiome precede KT rejection, we performed propensity score matching of patients with
238 available fecal samples before KT rejection to patients without KT rejection. Matched pre-rejection
239 and non-rejection groups 238 available fecal samples before KT rejection to patients without KT rejection. Matched pre-rejection
239 and non-rejection groups were comparable in age, sex, donor type, underlying CKD disease category
240 and time bet 239 and non-rejection groups were comparable in age, sex, donor type, underlying CKD disease category
240 and time between KT and sample (Supplemental Figure 4). Baseline characteristics of this subgroup
241 of patients ar 240 and time between KT and sample (Supplemental Figure 4). Baseline characteristics of this subgroup
241 of patients are shown in Table 2.
242 Rejection patients exhibited impaired renal function as compared to non-rejec

241 of patients are shown in Table 2.
242 Rejection patients exhibited impaired renal function as compared to non-rejection patients as
243 displayed by an increase in plasma creatinine within the first year post-KT, which 242 Rejection patients exhibited im
243 odisplayed by an increase in plasm
244 oduring follow-up (Fig 2A). This c 243 displayed by an increase in plasma creatinine within the first year post-KT, which remained the case
244 during follow-up (Fig 2A). This corresponds to most rejections in our cohort occurring within one
245 year post-K 244 during follow-up (Fig 2A). This corresponds to most rejections in our cohort occurring within one
245 year post-KT (Table 1 and 2). However, both rejection and normal progress patients reached a
246 similar minimal cre y ear post-KT (Table 1 and 2). However, both rejection and normal progress patients reached a
246 similar minimal creatinine as well as time to minimal creatinine (Fig 2B), indicating that initial graft
247 function was co 246 similar minimal creatinine as well as time to minimal creatinine (Fig 2B), indicating that initial graft
247 function was comparable between both groups. After the rejection event, kidney transplants
248 showed sustain 247 function was comparable between both groups. After the rejection event, kidney transplants
248 showed sustained graft dysfunction as indicated by higher minimal detected creatinine values after
249 their rejection even 248 showed sustained graft dysfunction as indicated by higher minimal detected creatinine values after
249 their rejection event as well as higher last recorded creatinine (Fig 2B). Of note, HLA mismatch
250 grade, rate of 249 their rejection event as well as higher last recorded creatinine (Fig 2B). Of note, HLA mismatch
250 grade, rate of AB0 incompatibility and delayed graft function were comparable between both groups
251 (Table 2).
252 250 grade, rate of ABO incompatibility and delayed graft function were comparable between both groups
251 (Table 2).
252 Microbiome analysis indicated alterations prior to the rejection event. Pre-rejection microbiome

251 (Table 2).
252 Microbiome analysis indicated alterations prior to the rejection event. Pre-rejection microbiome
253 composition was characterized by a distinct composition indicated by different clustering in the
254 P 252 Microbion
253 compositi
254 PCoA of
255 simpson e 253 composition was characterized by a distinct composition indicated by different clustering in the
254 PCoA of Bray-Curtis dissimilarity (Fig 2C), and lower alpha-diversity, reaching significance for
255 Simpson evenness 254 PCoA of Bray-Curtis dissimilarity (Fig 2C), and lower alpha-diversity, reaching significance for
255 Simpson evenness (Fig 2D). Patients who rejected the transplanted kidney had lower level of known
256 SCFA producers 255 Simpson evenness (Fig 2D). Patients who rejected the transplanted kidney had lower level of known
256 SCFA producers on genus level, like *Blautia, Clostridia,* or *Ruminococcus* torques group³⁸.
257 Interestingly, w 256 SCFA producers on genus level, like *Blautia*, *Clostridia*, or *Ruminococcus* torques group³⁸.
257 Interestingly, we observed an increase in bacteria typically found in CKD patients, like
258 *Fusobacterium*⁸, an SCFA producers on genus level, like *Blautia*, *Clostridia*, or *Ruminococcus* torques group³⁰.

257 Interestingly, we observed an increase in bacteria typically found in CKD patients, like

258 *Fusobacterium*⁸, and 258 *Fusobacterium*⁸, and disease-associated genera⁴⁰, such as *Strepcoccus*³⁹ and *Porphyromonas*⁴¹ (Fig
259 2E). *Fusobacterium*⁸, and disease-associated genera⁴⁰, such as Strepcoccus³⁹ and Porphyromonas⁴¹ (Fig. 258 Fusobacterium", and disease-associated genera⁴⁰, such as Strepcoccus²⁹ and Porphyromonas⁴⁴ (Fig.
259 2E).
13 259 2E).

260 261 infections was observed in the rejection group. We therefore carefully assessed the use of
262 immunosuppressants and anti-infective medication (Supplemental Figures 5-7), pointing out two
263 main differences, namely 262 immunosuppressants and anti-infective medication (Supplemental Figures 5-7), pointing out two
263 main differences, namely a lower number of patients on MPA at sampling date – likely due to the
264 viral complications 263 main differences, namely a lower number of patients on MPA at sampling date – likely due to the
264 viral complications – and a lower number of patients with basiliximab for induction in the rejection
265 group. Multiv 264 viral complications – and a lower number of patients with basiliximab for induction in the rejection
265 group. Multivariate analysis revealed no difference in microbiome composition in rejection patients
266 with or w 265 group. Multivariate analysis revealed no difference in microbiome composition in rejection patients
266 with or without basiliximab induction (Supplemental Figure 8), but MPA withdrawal showed a non-
267 significant sh 266 with or without basiliximab induction (Supplemental Figure 8), but MPA withdrawal showed a non-
267 significant shift in microbiome composition. Therefore, we performed the genus level differential
268 abundance analys 268 abundance analysis, including and excluding patients with MPA discontinuation, which closely
269 correlated (R= 0.98, p< 0.001) (Supplemental Figure 9). This indicates that the observed differences
270 were independent 269 correlated (R= 0.98, p< 0.001) (Supplemental Figure 9). This indicates that the observed differences
270 were independent of basiliximab induction or MPA discontinuation, respectively.
271 Lower SCFA production potent 270 were independent of basiliximab induction or MPA discontinuation, respectively.
271 **Lower SCFA production potential characterizes the pre-rejection microbiome**
272 Metabolites produced by microbiota are known to influ 270 were independent of basiliximab induction or MPA discontinuation, respectively.

271 Lower SCFA production potential characterizes the pre-rejection microbiome
272 Metabolites produced by microbiota are known to influence and modulate host
273 To identify potential candidates, we analyzed functional ca 271 Lower SCFA production potential characterizes the pre-rejection interobrane
272 Metabolites produced by microbiota are known to influence and modulate ho
273 To identify potential candidates, we analyzed functional ca To identify potential candidates, we analyzed functional capacities, predicted from our taxonomic
274 data using PICRUSt2³², identifying functional pathways in the significantly altered KOs using
275 GOmixer^{33,42}. We o 274 data using PICRUSt2³², identifying functional pathways in the significantly altered KOs using
275 GOmixer^{33,42}. We observed an overall clustering of rejection and non-rejection patients in the PCA
276 (Fig 3A). We data using PICRUSt2²², identitying functional pathways in the significantly altered KOs using
275 GOmixer^{33,42}. We observed an overall clustering of rejection and non-rejection patients in the PCA
276 (Fig 3A). We foun GOmixer^{33,42}. We observed an overall clustering of rejection and non-rejection patients in the PCA
276 (Fig 3A). We found an enrichment in proteolytic fermentation, reactive nitrogen and oxygen species,
277 and ammonia p 277 and ammonia pathways in the rejection group (Fig 3B, C). Conversely, overall sugar and polysaccharide utilization and mucus degradation were enriched in microbiomes from non-rejection controls (Fig 3B, C). Matching to 278 polysaccharide utilization and mucus degradation were enriched in microbiomes from non-rejection
279 controls (Fig 3B, C). Matching to the reduced number of SCFA-producing genera we found a
280 reduction in butyrate an 279 controls (Fig 3B, C). Matching to the reduced number of SCFA-producing genera we found a
280 reduction in butyrate and acetate fermentation pathways (Fig 3B, C), again highlighting the
281 reduction of SCFA production 280 reduction in butyrate and acetate fermentation pathways (Fig 3B, C), again highlighting the
281 reduction of SCFA production in stool samples preceding KT rejection (Fig 3B, C). Since SCFA and
282 regulatory immune fun 281 reduction of SCFA production in stool samples preceding KT rejection (Fig 3B, C). Since SCFA and
282 regulatory immune functions are closely linked, we aimed to confirm the reduction of SCFA
283 production using qPCR m regulatory immune functions are closely linked, we aimed to confirm the reduction of SCFA
283 production using qPCR measuring key enzymes for butyrate and propionate production. Overall, we
284 found a significant reductio 283 production using qPCR measuring key enzymes for butyrate and propionate production. Overall, we
284 found a significant reduction of butyryl-CoA:acetate CoA-transferase (but), a key enzyme for
14 284 found a significant reduction of butyryl-CoA:acetate CoA-transferase (but), a key enzyme for
284 found a significant reduction of butyryl-CoA:acetate CoA-transferase (but), a key enzyme for
14 284 found a significant reduction of butyryl-CoA:acetate CoA-transferase (but), a key enzyme for

285 butyrate production, and methylmalonyl-coA decarboxylase (mmax), a key enzyme for propionate
286 production (Fig 4A, B). Another central enzyme for butyrate synthesis, butyryl-CoA dehydrogenasee
287 (bcd), was reduced 287 (bcd), was reduced without reaching significance (Fig 4A, B). Taken together, a key feature of the gut
288 microbiome in samples from patients preceding KT rejection is a marked reduction of the potential
289 to produ 287 (bcd), was reduced without reaching significance (Fig 4A, B). Taken together, a key reature of the gut
288 microbiome in samples from patients preceding KT rejection is a marked reduction of the potential
289 Microbiom 289 to produce SCFA.
289 to produce SCFA.
290 Microbiome alterations normalize post-rejection is a marked reduction of the post-reduction of the post-
291 As our initial analysis indicated a potential shift post-rejection,

290 Microbiome alter
291 As our initial ana
292 from our matche 290 Microbiome alterations normalize post-rejection
291 As our initial analysis indicated a potential shift
293 rejection and n=54 non-rejection patients). PCo 292 From our matched cohort within a timeframe of 90 to 1000 days after the first sample (n=21
293 rejection and n=54 non-rejection patients). PCoA using Bray-Curtis dissimilarity shows that the
294 microbiome composition 293 rejection and n=54 non-rejection patients). PCoA using Bray-Curtis dissimilarity shows that the
294 microbiome composition becomes more similar to the non-rejection control group in post-rejection
295 samples (Fig 5A). 294 microbiome composition becomes more similar to the non-rejection control group in post-rejection
295 samples (Fig 5A). Over a similar time frame the microbiome composition of non-rejection controls
296 was stable. The 295 samples (Fig 5A). Over a similar time frame the microbiome composition of non-rejection controls
296 was stable. The same trend could be observed for the number of detected OTUs, Shannon diversity
297 and Simpson evenn was stable. The same trend could be observed for the number of detected OTUs, Shannon diversity
297 and Simpson evenness (Fig 5B). Next, we analyzed microbiome alterations post-rejection on genus
298 level (Fig 5C). While and Simpson evenness (Fig 5B). Next, we analyzed microbiome alterations post-rejection on genus
298 kevel (Fig 5C). While the non-rejection control showed no significant alterations, most genera
299 dysregulated preceding 298 level (Fig 5C). While the non-rejection control showed no significant alterations, most genera
299 dysregulated preceding rejection were significantly changed in the opposite direction after the KT
200 rejection event 299 dysregulated preceding rejection were significantly changed in the opposite direction after the KT
200 rejection event (Fig 5C). Especially known genera of SCFA production like *Blautia* and
301 *Faecalibacterium* incr 299 depending rejection event (Fig 5C). Especially known genera of SCFA production like *Blautia* and
201 *Faecalibacterium* increased, while disease-associated genera like *Fusobacterium* and *Streptococcus*
202 decreased 301 Faecalibacterium increased, while disease-associated genera like Fusobacterium and Streptococcus
302 decreased (Fig 5D).
303 Taken together, we observe a normalization of the pre-rejection microbiome towards the normal

302 *Tuecalibacterium* increased, while disease-associated genera like *Fusobacterium* and *Streptococcus*
303 Taken together, we observe a normalization of the pre-rejection microbiome towards the normal KT
304 signature 303 Taken together, we
303 Taken together, we
305 microbiome favors 304 signature in a longitudinal follow-up analysis. One could speculate that a lack of normalization of the
305 microbiome favors chronic rejections. Due to insufficient sample size, we could not further test this
306 hypo 305 microbiome favors chronic rejections. Due to insufficient sample size, we could not further test this
306 hypothesis in this study.
307 The microbiome signature in kidney transplant rejection is a prolonged CKD signatu 306 hypothesis in this study.
307 The microbiome signature in kidney transplant rejection is a prolonged CKD signature

 307 The microbiome signatu 307 The microbiome signature in kidney transplant rejection is a prolonged CKD signature

308 309 partial overlap with a microbiome features of pediatric CKD patients recently published by us⁸.
310 Therefore, we hypothesized that the microbiome alterations preceding KT rejection in parts reflects
311 a prolonged partial overlap with a microbiome features of pediatric CKD patients recently published by us⁹.

310 Therefore, we hypothesized that the microbiome alterations preceding KT rejection in parts reflects

311 a prolonged CK 311 a prolonged CKD signature after KT. Therefore, we re-analyzed a recently published 16S rRNA gene
312 sequencing dataset from CKD patients (n=217) and healthy controls (n=479)²⁶. In line with our
313 hypothesis, the sequencing dataset from CKD patients (n=217) and healthy controls (n=479)²⁶. In line with our
313 by hypothesis, the KT rejection signature correlated with the CKD signature in the dataset from Ren et
314 al. (for the 12 sequencing dataset from CKD patients (n=217) and healthy controls (n=479)²⁰. In line with our
hypothesis, the KT rejection signature correlated with the CKD signature in the dataset from Ren et
al. (for the 120 common g 314 al. (for the 120 common genera, R= 0.19, p= 0.033) (Fig 6A). In particular, the overlap of both
315 datasets also held true for the reduction of important SCFA producers like *Blautia* and
316 *Faecalibacterium*, as we 315 datasets also held true for the reduction of important SCFA producers like *Blautia* and
316 *Faecalibacterium*, as well as for the increase in *Streptococcus* and *Fusobacterium*, with the latter not
317 reaching sign Faecalibacterium, as well as for the increase in *Streptococcus* and *Fusobacterium*, with the latter not
317 reaching significance in the CKD-HC comparison (Fig 6A, B). Lastly, we performed a targeted analysis
318 of bact Facedialities in the CKD-HC comparison (Fig 6A, B). Lastly, we performed a targeted analysis
318 of bacterial taxa captured by our *but, bcd* and *mmdA* assays. Overall, the abundance of butyrate and
319 propionate produci 318 of bacterial taxa captured by our *but, bcd* and *mmdA* assays. Overall, the abundance of butyrate and
319 propionate producing taxa was lower in CKD patients mirroring the effect we observed in
320 microbiome samples 319 propionate producing taxa was lower in CKD patients mirroring the effect we observed in
320 microbiome samples preceding KT rejection (Fig 6C).
321 In aggregate, our data indicate that the pre-rejection signature we ob

microbiome samples preceding KT rejection (Fig 6C).
321 In aggregate, our data indicate that the pre-rejection signature we observed in our cohort might in
322 part be a sustained CKD signature. Especially the lack of fibe 321 In aggregate, our data indicate that the pre-rejection
322 part be a sustained CKD signature. Especially the lack
323 a key feature found in both disease states. 322 part be a sustained CKD signature. Especially the lack of fiber fermenting, SCFA-producing bacteria is
323 a key feature found in both disease states. 323 a key feature found in both disease states.

323 a key feature found in both disease states.

325 In the present s
325 In the present s
327 dependent CKD, 326 allograft rejection. KT remains the best treatment option for patients with advanced and dialysis-
327 dependent CKD, but graft availability is limited. Therefore, the improvement of graft survival and
328 prevention o 330 and without rejection, which are of potential prognostic and therapeutic value. 328 prevention of allograft rejection are paramount. For the first time, we describe compositional and
329 functional differences in the microbiome in a representative cohort of 217 transplant patients with
330 and without 329 functional differences in the microbiome in a representative cohort of 217 transplant patients with
330 and without rejection, which are of potential prognostic and therapeutic value.
331 Our analysis of longitudinally

330 and without rejection, which are of potential prognostic and therapeutic value.
331 Our analysis of longitudinally collected fecal samples unveils a dynamic trajectory of microbiome
332 recovery post KT, which undertak 331 Our analysis of longitudinally collected fecal samples unveils a dynamic traje
332 recovery post KT, which undertakes a gradual shift towards a more stable and
333 composition⁴⁰ over time. This gradual process is mar recovery post KT, which undertakes a gradual shift towards a more stable and healthier microbiota
333 composition⁴⁰ over time. This gradual process is marked by the enrichment of bacterial taxa
334 associated with shortcomposition⁴⁰ over time. This gradual process is marked by the enrichment of bacterial taxa
334 associated with short-chain fatty acid (SCFA) production (such as *Roseburia, Faecalibacterium*), and a
335 loss of diseasecomposition⁴⁰ over time. This gradual process is marked by the enrichment of bacterial taxa
associated with short-chain fatty acid (SCFA) production (such as *Roseburia, Faecalibacterium*), and a
loss of disease-associat 335 loss of disease-associated taxa (such as *Streptococcus*). These regenerative microbiome shifts post
336 KT are significantly perturbed in the case of graft rejection. Preceding the rejection event, we
337 observed pro 335 Ioss of disease-associated taxa (such as *Streptococcus)*. These regenerative interoblome shifts post
336 KT are significantly perturbed in the case of graft rejection. Preceding the rejection event, we
337 observed pr 337 Subserved profound alterations in microbiome composition, characterized by a diminished diversity
338 and underrepresentation of SCFA-producing bacterial populations. Notably, these alterations tend to
339 normalize po 338 and underrepresentation of SCFA-producing bacterial populations. Notably, these alterations tend to
339 normalize post KT rejection events. We consider these observations to be of potential functional
340 relevance for 339 normalize post KT rejection events. We consider these observations to be of potential functional
340 relevance for allograft immunity due to the known immunomodulatory properties of SCFA
341 reference^{9,17}. Although o relevance for allograft immunity due to the known immunomodulatory properties of SCFA
341 reference^{9,17}. Although our study was not designed to show causality, our results suggest that the
342 microbiome is an important 341 reference^{9,17}. Although our study was not designed to show causality, our results suggest that the
342 microbiome is an important modulator of immunologic events after KT - an observation that may
343 also have prog reference^{9,27}. Although our study was not designed to show causality, our results suggest that the
342 microbiome is an important modulator of immunologic events after KT - an observation that may
343 also have prognosti

343 also have prognostic significance for the prevention of KT rejection and graft survival.
344 The observed gradual normalization of the microbiome composition after KT aligns for several
345 bacterial taxa the normaliza 344 The observed gradual normalization of the microbiome composition after KT alignificant and bacterial taxa the normalization of known alterations in the gut microbiome of CKD particle microbiome of CKD patients is relat 345 bacterial taxa the normalization of known alterations in the gut microbiome of CKD patients. The gut
346 microbiome of CKD patients is relatively well investigated. It is characterized by a lower diversity and
347 a sh 346 microbiome of CKD patients is relatively well investigated. It is characterized by a lower diversity and
347 a shift in metabolic output^{6,8,26,43}. While the production of SCFA metabolites, recognized for their
348 an 347 a shift in metabolic output^{68,26,43}. While the production of SCFA metabolites, recognized for their
348 anti-inflammatory effects⁹, is reduced⁸, we and others have observed an increase in the production
17 a shift in metabolic output $\frac{32.25,33}{3}$. While the production of SCFA metabolites, recognized for their
348 anti-inflammatory effects⁹, is reduced⁸, we and others have observed an increase in the production
17 anti-inflammatory effects⁻
-
-
-348 anti-inflammatory effects", is reduced", we and others have observed an increase in the production and the
17
17

of microbiome-derived uremic toxins like TMA⁴⁴, p-cresols³⁵ and indoles^{9,46}. Of note, the microbiome
of CKD patients is characterized by an increase of bacterial taxa frequently linked to health-to-
351 disease trans 354 transition in the microbiome. Dysbiotic microbiome states in KT patients have been described by disease transition in large representative metagenomic studies^{30,47}. In the present study, we observe
a decrease of known pathogenic bacteria and increase in beneficial commensals over the course of
more than three years 353 more than three years post KT. Thus, the observed changes are reminiscent of a CKD-to-health
354 transition in the microbiome. Dysbiotic microbiome states in KT patients have been described by
355 others^{10,13}. Swarte 354 transition in the microbiome. Dysbiotic microbiome states in KT patients have been described by
355 others^{10,13}. Swarte and colleagues demonstrated that lower gut microbial diversity in kidney and liver
356 transpla others^{10,13}. Swarte and colleagues demonstrated that lower gut microbial diversity in kidney and liver
356 transplant recipients is associated with an increased overall mortality¹³. As graft survival is the most
357 im others^{20,13}. Swarte and colleagues demonstrated that lower gut microbial diversity in kidney and liver
1356 transplant recipients is associated with an increased overall mortality¹³. As graft survival is the most
1357 transplant recipients is associated with an increased overall mortality²⁵. As graft survival is the most

important predictor of overall medium- and long-term survival after KT², we hypothesize that gut

bacterial dive

important predictor of overall medium- and long-term survival after KT², we hypothesize that gut
bacterial diversity may also be important for graft survival.
359 , We demonstrate that alterations of the gut microbiome, 359 bacterial alteration, may also be important for graft survival.
360 alterations in the abundance of more than 50 bacte
361 Microbiome composition preceding graft rejection was of 350 alterations in the abundance of more than 50 bacterial taxa, occur before graft rejection.
351 Microbiome composition preceding graft rejection was characterized by several typical disease-
352 associated species. Most 361 Microbiome composition preceding graft rejection was characterized by several typical disease-
362 associated species. Most prominent and similar to the analyzed CKD signature, we found an increase
363 in *Streptococcu* 365 (although not reaching significance in the cohort we reanalyzed²⁶ as compared to other studies⁸) was 363 in *Streptococcus. Streptococcus spp.* were recently correlated to subclinical atherosclerotic lesions in
364 a cohort of nearly 9000 patients³⁹. Another genus found to be upregulated in rejection and CKD
365 (althou a cohort of nearly 9000 patients³⁹. Another genus found to be upregulated in rejection and CKD
365 (although not reaching significance in the cohort we reanalyzed²⁶ as compared to other studies⁸) was
366 *Fusobacteri* a cohort of nearly 9000 patients³⁹. Another genus found to be upregulated in rejection and CKD
(although not reaching significance in the cohort we reanalyzed²⁶ as compared to other studies⁸) was
366 *Fusobacterium.* (although not reaching significance in the cohort we reanalyzed²⁶ as compared to other studies⁹) was
366 *Fusobacterium. Fusobacterium nucleatum* was recently described as a driver of uremic toxins
367 production and C production and CKD progression⁴³, again underscoring the notion of a prolonged CKD signature in
368 the microbiome as a potential risk factor for graft rejection. We and others have shown that SCFA
369 are relevant bacte production and CKD progression⁴³, again underscoring the notion of a prolonged CKD signature in
368 the microbiome as a potential risk factor for graft rejection. We and others have shown that SCFA
369 are relevant bacte are relevant bacterial metabolites for immune homeostasis in CKD as well as for other chronic
370 diseases^{8,17,48-50}. Using computational prediction of functional microbiome properties (PICRUSt2³²),
371 we show a signi diseases^{8,17,48-50}. Using computational prediction of functional microbiome properties (PICRUSt2³²),
371 we show a significantly reduced potential of the gut microbiome to produce SCFA. PICRUSt2 predicts
372 microbiome diseases^{9,27,48}55. Using computational prediction of functional microbiome properties (PICRUSt2⁵²⁴),
371 we show a significantly reduced potential of the gut microbiome to produce SCFA. PICRUSt2 predicts
372 microbiom microbiome functions such as SCFA production based on the available genomic data and the inferred
presence of genes from closely related taxa³². PICRUSt accuracy significantly decreases for microbes
374 with fewer close presence of genes from closely related taxa³². PICRUSt accuracy significantly decreases for microbes
374 with fewer close relatives in reference databases⁵¹. Acknowledging this limitation, we validated the
18 presence of genes from closely related taxa³⁴. PICRUSt accuracy significantly decreases for microbes
with fewer close relatives in reference databases⁵¹. Acknowledging this limitation, we validated the
18 374 with fewer close relatives in reference databases³⁴. Acknowledging this limitation, we validated the 18
18

375

376 the microbiome may be functionally implied in the development of graft rejection.
377 A recent meta-analysis concluded that immune cell therapies, including transfer of regulatory T cells
378 (Treg), are a useful appr 377 A recent meta-analysis concluded that immune cell therapies, including transfer of
378 (Treg), are a useful approach to reduce immunosuppression during KT²⁰. The find
379 and others suggest that SCFA warrant scientif 378 (Treg), are a useful approach to reduce immunosuppression during KT^{20} . The findings of our study
379 and others suggest that SCFA warrant scientific attention as Treg-modulating bacterial metabolites.
380 SCFA have (Treg), are a useful approach to reduce immunosuppression during KT²⁰. The findings of our study
and others suggest that SCFA warrant scientific attention as Treg-modulating bacterial metabolites.
SCFA have been shown t SCFA have been shown to influence the function and differentiation of Treg-both through GPR
signaling and HDAC inhibition^{9,52}. Experimental transplantation models demonstrate the efficacy of
SCFA treatments through induc 381 signaling and HDAC inhibition^{9,52}. Experimental transplantation models demonstrate the efficacy of
382 SCFA treatments through induction of Treg. Kidney transplants showed a prolonged survival in
383 animals fed a hi signaling and HDAC inhibition⁹⁷². Experimental transplantation models demonstrate the efficacy of
382 SCFA treatments through induction of Treg. Kidney transplants showed a prolonged survival in
383 animals fed a high fi 383 animals fed a high fiber diet or directly the SCFA acetate⁵³. Thus, the rapid attainment of a healthy
384 SCFA production potential could be relevant for Treg function and the prevention of rejection events
385 as w animals fed a high fiber diet or directly the SCFA acetate⁵⁵. Thus, the rapid attainment of a healthy
SCFA production potential could be relevant for Treg function and the prevention of rejection events
385 as well as o

385 as well as other comorbidities found after KT⁵⁴.
386 Two recent smaller studies similarly suggest alterations of the microbiome in patients with acute
387 rejection (n=3 patients, including both TCMR and antibody-me as well as other comorbidities found after KT⁻⁴.

386 . Two recent smaller studies similarly suggest a

387 . rejection (n=3 patients, including both TCMR

388 . antibody-mediated rejection (n=24)⁵⁶. While the

389 . 386 Two recent smaller studies similarly suggest alterations of the microbiome in patients with acute
387 rejection (n=3 patients, including both TCMR and antibody-mediated rejection)⁵⁵ or patients with
388 antibody-med rejection (n=3 patients, including both TCMR and antibody-mediated rejection)³⁵ or patients with
antibody-mediated rejection (n=24)⁵⁶. While the first study is severely limited by its low sample size,
the second study antibody-mediated rejection (n=24)⁵⁶. While the first study is severely limited by its low sample size,
389 the second study – albeit focusing on ABMR compared to our focus on TCMR – described on a broad
390 scale simila 390 scale similar features like a reduced alpha diversity. Of note, the observed microbiome alterations in
391 our study preceding rejection events normalized during longitudinal follow-up. Future studies are
392 needed to 391 our study preceding rejection events normalized during longitudinal follow-up. Future studies are
392 needed to investigate whether persistent microbiome alterations influence the risk for chronic
393 rejection.
394 Th 392 needed to investigate whether persistent microbiome alterations influence the risk for chronic
393 rejection.
394 The circumstance that fecal samples were not consistently available from all patients at all
395 timenoi

393 rejection.
394 The circumstance that fecal samples were not consistently available from all patients at all
395 timepoints in our multi-center cohort limits the validity of our study. However, in non-rejection
396 pati 394 The circu
395 timepoint:
396 patients a 395 time points in our multi-center cohort limits the validity of our study. However, in non-rejection
396 patients a minimum sample number of two stool samples per patient was not undercut, which
397 enabled the longitudi Basis patients a minimum sample number of two stool samples per patient was not undercut, which
1397 enabled the longitudinal character of our study. Despite this, our findings clearly indicate a gradual
1398 shift towards 397 enabled the longitudinal character of our study. Despite this, our findings clearly indicate a gradual
398 shift towards a more stable microbiome state post-transplantation. A further limitation is the lack of
399 meta 398 shift towards a more stable microbiome state post-transplantation. A further limitation is the lack of
399 metabolomic measurements in our study, which we replaced with specific quantifications of the
19 399 metabolomic measurements in our study, which we replaced with specific quantifications of the lack $\frac{3}{2}$ 99 metabolomic measurements in our study, which with specific $\frac{1}{2}$

408 decipher the interaction of SCFA and Treg in KT patients and to test the potential of microbiome-
409 decipher the interaction of SCFA and Treg in KT patients and to test the potential of microbiome-
409 decipher the i

 410

411 Funding
412 This stud
413 (https://w
414 additiona (https://www.dzif.de/en/working-group/transplant-cohort), support code TTU 07.701, and
414 additional DZIF funding under TTU 07.916 to M. Gerhard, D. Schinderl and J. Holle. J Holle was
415 supported by the Else Kröner-Fre additional DZIF funding under TTU 07.916 to M. Gerhard, D. Schinderl and J. Holle. J Holle was
415 supported by the Else Kröner-Fresenius Stiftung (2023_EKEA.127). N. Wilck was supported by the
416 European Research Counci Example 19 additional Daming and the Control of M. Dominal Pole in the Pole in the United Water of Aleman Supported by the
416 European Research Council under the European Union's Horizon 2020 research and innovation
417 p European Research Council under the European Union's Horizon 2020 research and innovation
417 program grant 852796 and by the Corona Foundation in the German Stifterverband. H.
418 Bartolomaeus and N. Wilck were supported 417 program grant 852796 and by the Corona Foundation in the German Stifterverband. H.
418 Bartolomaeus and N. Wilck were supported by the BMBF, Foerderkennzeichen 01EJ2202A (TAhRget
419 Consortium). 418 Bartolomaeus and N. Wilck were supported by the BMBF, Foerderkennzeichen 01EJ2202A (TAhRget
419 consortium).
Acknowledgement 419 Bartolomaeus and N. Michel experies ay the BMBF, Formational Marine Chinesen (Thinget
420 Acknowledgement
421 We thank the members of the German Center of Infection Research Transplant Cohort, in particular

420 **Acknowledg**
421 We thank the
422 the members 420 **Acknowledgement**
421 We thank the member
423 Dr. Tina Ganzenmülle 422 the members of the executive board and the scientific steering committee: Dr. Susanne Delecluse,
423 Dr. Tina Ganzenmüller, Dr. Bärbel Fösel, Dr, Caroline Klett-Tammen, Dr. Thomas F. Schulz, Dr. Uwe
424 Heemann, Dr. Th 123 Dr. Tina Ganzenmüller, Dr. Bärbel Fösel, Dr, Caroline Klett-Tammen, Dr. Thomas F. Schulz, Dr. Uwe
124 Heemann, Dr. Thomas Giese, Dr. Philip Ehlermann, Dr. Rasmus Rivinius, Dr. Uta Merle, Dr. Peter
125 Lang, Dr. Martin 424 Heemann, Dr. Thomas Giese, Dr. Philip Ehlermann, Dr. Rasmus Rivinius, Dr. Uta Merle, Dr. Peter
425 Lang, Dr. Martin Hildebrandt, Dr. Christine S. Falk, Dr. Burkhard Tönshoff, Dr. Anette Melk, Dr.
426 Thomas Illig, Dr. 1444 Hermann, Dr. Martin, Dr. Johnson, Dr. Anthres Minnes, Dr. Dr. Martin, Dr. Lensen, Dr. 1444
1425 Lang, Dr. Martin Hildebrandt, Dr. Christine S. Falk, Dr. Burkhard Tönshoff, Dr. Anette Melk, Dr.
1426 Data sharing statem 14426 Thomas Illig, Dr. Berit Lange, and Dr. Thomas Iftner.
227 **Data sharing statement**
228 Deidentified metagenomic sequencing data for samples of the Transplant Cohort of the DZIF can be

434 Statistical-Analysis.

227 **Data sharing statement**
428 Deidentified metagenomic sequencing data for sam
429 accessed from the European Nucleotide Archi 227 Data sharing statement

428 Deidentified metagenomic

429 accessed from the Euro

430 (https://www.ebi.ac.uk/en accessed from the European Nucleotide Archive under accession number PRJNA1106540
430 (https://www.ebi.ac.uk/ena/browser/view/PRJNA1106540). Access to pseudonymized phenotype
431 data requires approval from the scientific (https://www.ebi.ac.uk/ena/browser/view/PRJNA1106540). Access to pseudonymized phenotype
data requires approval from the scientific steering committee of the DZIF Transplant cohort. The
source code and the summary data und data requires approval from the scientific steering committee of the DZIF Transplant cohort. The
432 source code and the summary data underlying all figures used to generate the results for the
433 analysis are available a 1432 source code and the summary data underlying all figures used to generate the results for the analysis are available at https://github.com/rosareitmeir/DZIF-Tx-Cohort-Data-Cleaning-and-Statistical-Analysis. 433 analysis are available at https://github.com/rosareitmeir/DZIF-Tx-Cohort-Data-Cleaning-and-Statistical-Analysis.
434 Statistical-Analysis.

436 Supplemental Material
437 Supplemental Figures
438 Supplemental Figure 1. St
440 Supplemental Figure 2.

437 Supplemental Figure 1.1
439 patients and final sample
440 Supplemental Figure 2
441 Horizontal lines indicate supplemental Figure 1. Study design. Flow chart of the study design with inclusion and exclusion of
patients and final sample number.
440 Supplemental Figure 2. Observed OTU in rejection (red) and non-rejection (blue) pati Example number and final sample number.

440 Supplemental Figure 2. Observe

442 Vertical lines on top of the x-axis in

443 Supplemental Figure 3. Impact of

Supplemental Figure 2. Observed OTU in rejection (red) and non-rejection (blue) patients.
441 Horizontal lines indicate the number of detected OTU, shaded area is the 95% confidence interval.
442 Supplemental Figure 3. Imp Vertical lines on top of the x-axis indicate rejection events.
443 Supplemental Figure 3. Impact of rejection state on gut microbiome composition. Analysis of fecal
444 samples from patients experiencing kidney rejection a Supplemental Figure 3. Impact of rejection state on gut n
144 Samples from patients experiencing kidney rejection at
145 Experiencing graft rejection. Heatmap showing associant
146 Transplant rejection. Meta-variables with 3444 samples from patients experiencing kidney rejection at any time composition. Analysis of iceal
444 samples from patients experiencing kidney rejection at any time compared to patients never
445 experiencing graft rej experiencing graft rejection. Heatmap showing associations of bacterial genera with kidney

446 transplant rejection. Meta-variables with significant association are shown. Stars indicate de-

447 confounded significant as transplant rejection. Meta-variables with significant association are shown. Stars indicate deconfounded significant associations; grey dots indicate confounded associations. \degree /*FDR< 0.1,
448 \degree /**FDR< 0.01, \degree \degree

451 indicate non-rejection before (left) and after (right) propensity score matching. Rejection is shown in confounded significant associations; grey dots indicate confounded associations. \degree /*FDR< 0.1,
448 \degree \degree /**FDR< 0.01, \degree \degree /***FDR< 0.001.
449 **Supplemental Figure 4: Matching of rejection and non-rejection patien** 448 °°/**FDR< 0.01, °°°/***FDR< 0.001.
449 **Supplemental Figure 4: Matching**
450 metavariables before (left) and aft
451 indicate non-rejection before (left) a
452 black. Supplemental Figure 4: Matching of rejection and non-rejection patients. Plots indicate

450 metavariables before (left) and after propensity score matching (right). Grey bars/ histogram

452 black.

453 Supplemental Figur

indicate non-rejection before (left) and after (right) propensity score matching. Rejection is shown in
452 black.
453 **Supplemental Figure 5: Immunosuppressive treatment at the time of transplantation (A) and at
454 the t** black.
452 black.
453 **Supplemental Figure 5: Immunosuppressive treatment at the time of transplantation (A) and at
454 the time of fecal sampling (B). Fecal samples were analysed from patients before experiencing graft
45** 453 **Supple**
454 the tir
455 rejecti
456 plotsii Supplemental Figure 5: Immunosuppressive treatment at the time of transplantation (A) and at
the time of fecal sampling (B). Fecal samples were analysed from patients before experiencing graft
rejection (Rejection, red) an

ric time of fecal sampling (B). Fecal samples were analysed from patients before experiencing graft
rejection (Rejection, red) and propensity score matched (1:2) controls (normal progress, blue). Bar
456 bots indicate medi plots indicate medication at A) transplantation and B) fecal sampling.

457 Supplemental Figure 6. Tacrolimus plasma levels in matched rejection and non-rejection patients.

458 A) Tacrolimus plasma levels of n=92 patients 457 **Supplemental Figure 6. Tacrolimus plasma levels in matched rejecti**
458 A) Tacrolimus plasma levels of n=92 patients (matched cohort) for the
469 and sample collection before rejection event (n=121 data points of 51
4 3457 Supplemental Figure 6. Tacrolimus plasma levels in matched rejection and non-rejection patients.
458 A) Tacrolimus plasma levels of n=92 patients (matched cohort) for the time between transplantation
460 51 data point and sample collection before rejection event (n=121 data points of 51 patients for non-rejection and
460 51 data points of 23 patients for rejection group). B) Difference of target to actual values of
461 Tacrolimus. Targe 460 51 data points of 23 patients for rejection group). B) Difference of target to actual values of
461 Tacrolimus. Target values have been determined by the respective clinical recommendations after
462 kidney transplanta

Frame of 23 patition of 1991 and points of 1991 and the respective clinical recommendations after
A62 kidney transplantation.
A63 Supplemental Figure 7: Anti-infective medications used between kidney transplantation and fe kidney transplantation.
463 Supplemental Figure 7: Anti-infective medications used between kidney transplantation and fecal
464 Sampling. Anti-infective medication used between kidney transplantation and fecal sampling for 1922 **Engine Promptunished Supplemental Figure 7:**
464 **sampling.** Anti-infective
465 matched cohort (norm
466 therapeutic is shown. 34464 sampling. Anti-infective medication used between kidney transplantation and fecal sampling for the matched cohort (normal progress, blue; rejection, red). Medication used both preventive and therapeutic is shown. 324 sampling. Anti-infective medication used between kidney transplantation and fecal sampling for the
465 matched cohort (normal progress, blue; rejection, red). Medication used both preventive and
466 therapeutic is show 1466 matrice cohort (normal progress) and y regions, red). Medication used both preventive and the theoretic is shown. 466 therapeutic is shown.

Examplemental Figure 8: Impact of bashikimab induction therapy on the gut introduction

468 composition. PCoA on Bray-Curtis Dissimilarity of the 16S amplicon sequencing in rejection patients

469 with (brown) and without

examples composition. PCoA on Bray-Curtis Dissimilarity of the 16S amplicon sequencing in rejection patients
469 with (brown) and without (orange) basiliximab use during induction. Statistical testing using
471 Supplementa ERMANOVA shows no difference.
471 Supplemental Figure 9: Impact of mycophenole (MPA) withdrawal on the gut microbiome
472 composition. A) PCoA on Bray-Curtis Dissimilarity of the 16S amplicon sequencing in rejection
473 pa 470 **Supplemental Figure 9: Impact**
472 **composition.** A) PCoA on Bray-Cu
473 patients with (light green) and witl
474 PERMANOVA shows no difference,
475 effect sizes in the whole rejectio Examplemental Figure 9: Impact of Inycophenole (MPA) withdrawal off the gat iniciousline

472 composition. A) PCoA on Bray-Curtis Dissimilarity of the 16S amplicon sequencing in rejection

473 per extends with (light green extract composition. A) PCoA on Bray-Curtis Dissimilarity of the 16S ampline in sequencing in rejection
patients with (light green) and without (dark green) MPA at fecal sampling. Statistical testing using
474 PERMANOVA sh FERMANOVA shows no difference, although some distinct clustering can be seen. B) Correlation of
475 effect sizes in the whole rejection cohort (x-axis) and the cohort excluding patients with MPA
476 withdrawing (y-axis). A effect sizes in the whole rejection cohort (x-axis) and the cohort excluding patients with MPA
476 withdrawing (y-axis). Axis shows Cliff's deltas for all detected genera in the gut microbiome.
477 Spearman correlations, i withdrawing (y-axis). Axis shows Cliff's deltas for all detected genera in the gut microbiome.
477 Spearman correlations, individual significances for genera using univariate testing in
478 metadeconfoundR.
479 Sunnlementa 477 Spearman correlations, individual significances for genera using univariate testing in
478 metadeconfoundR.
479 **Supplemental Tables** 478 metadeconfoundR.
479
480 Supplemental Tables
481 Supplemental Table 1: Clinical variables used for deconfounding of microbiome features

- 479
480 **Supplemental Table
481 Supplemental Table**
483 Supplemental Table ---
480
481
482
-
- 480 Supplemental Table 1:
481 Supplemental Table 1:
483 Supplemental Table 3:
483 Supplemental Table 3:
484 propionate synthesis an Supplemental Table 2: Primers used for 16S sequencing.
482 Supplemental Table 2: Primers used for 16S sequencing.
483 Supplemental Table 3: Bacterial species included to the gene targeting assays for b
484 propionate synth Supplemental Table 3: Bacterial species included to the
483 Supplemental Table 3: Bacterial species included to the
484 propionate synthesis and corresponding primer sequence
485 3433 Supplemental Table 3: Bacterial species included to the gene targeting assays for butyrate and
propionate synthesis and corresponding primer sequences.
485

484 propionate synthesis and corresponding primer sequences.

- 486 Tables
487 Table 1.
488 patients
489 Disease
- Frame 1. Clinical baseline characteristics total cohort. Kidney transplant (KT) donors, pre-KT citize

489 Diseases (DZIF) were analyzed in this study. Data are presented as median and interquartile rang

490 absolute valu
-
-

493 (KT) recipients from the transplant cohort of the German Center of Infectious Diseases (DZIF) were
494 analyzed in this study. Samples were obtained after KT from all patients, but before rejection in the
495 rejection analyzed in this study. Samples were obtained after KT from all patients, but before rejection in the
495 (expection group. Data are presented as median and interquartile range or absolute values and
496 (expection group. rejection group. Data are presented as median and interquartile range or absolute values and
496 percentages as appropriate. Primary graft dysfunction: patient still required dialysis three months
497 after KT. Delayed gra experience of the matter processes as appropriate. Primary graft dysfunction: patient still required dialysis three months
after KT. Delayed graft function: patient required one to three dialysis treatments after KT.
non-r

498

498 499

500 Figure legends
501 Figure 1. Longitude
503 transplantation (1. Subsemial changes to the gat intervalsion after kidney transplantation and impact of
502 **allograft rejection.** 16S rRNA gene amplicon sequencing from fecal material from kidney
503 transplantation (KT)-related samples transplantation (KT)-related samples from the transplant cohort of the German Center of Infectious
504 Diseases (DZIF). Samples were grouped according to healthy kidney donors, pre-KT, 0-3 months post-
505 KT, 3-12 months, 504 Diseases (DZIF). Samples were grouped according to healthy kidney donors, pre-KT, 0-3 months post-
505 KT, 3-12 months, 12-24 months and over 24 months. A) PCoA based on Bray-Curtis dissimilarity.
506 Quantification of 508 diversity in kidney transplant recipients with and without graft rejection at any point is shown in F-H. 506 Quantification of the B) Number of detected OTU, C) Shannon diversity, and D) Simpson evenness. E)
507 Cuneiform plot displaying significantly altered bacteria post-transplantation over time. Microbial
508 diversity in 507 Cuneiform plot displaying significantly altered bacteria post-transplantation over time. Microbial
508 diversity in kidney transplant recipients with and without graft rejection at any point is shown in F-H.
509 F) Pri Eurieriorm plot displaying significantly altered bacteria post-transplantation over time. Microbial

508 diversity in kidney transplant recipients with and without graft rejection at any point is shown in F-H.

509 F) Prin 509 F) Principal Coordinates Analysis (PCoA) based on Bray-Curtis dissimilarity illustrates the distinct
510 clustering of patients who experienced graft rejection (red circles) from those without rejection
511 (blue circl 510 clustering of patients who experienced graft rejection (red circles) from those without rejection
511 (blue circles). Red and blue squares mark the respective centroids. G+H) Longitudinal analysis of
512 microbial dive 511 (blue circles). Red and blue squares mark the respective centroids. G+H) Longitudinal analysis of
512 microbial diversity, depicted through Shannon diversity and Simpson evenness indices, shows a
513 reduction in both microbial diversity, depicted through Shannon diversity and Simpson evenness indices, shows a
513 reduction in both measures within the first-year post-transplantation for patients undergoing
514 rejection. Vertical red ba Figures in the term of the
513 reduction in both measures within the first-year post-transplantation for patients undergoing
515 in microb Figures 14 rejection. Vertical red bars indicate individual rejection events over time, coinciding with alterations
515 in microbial diversity.
516 **Figure 2. Microbiome alteration precede kidney transplant rejection.** Pat

515 in microbial diversity.
516 in microbial diversity.
517 **Figure 2. Microbiome alteration precede kidney transplant rejection.** Patients with available fecal
518 samples prior to kidney rejection (Rejection group) for p 515 in microbial diversity.
516
517 **Figure 2. Microbiome**
518 samples prior to kidn
519 without kidney rejecti 517
518
519
520 samples prior to kidney rejection (Rejection group) for propensity score matched (1:2) to patients
519 without kidney rejection (Non-Rejection group). A) Plasma creatinine levels are depicted over time,
520 displaying a co samples prior to kind, rejection (Non-Rejection group). A) Plasma creatinine levels are depicted over time,
520 displaying a consistent increase within the first year post-transplant in patients who experienced
521 graft r 520 displaying a consistent increase within the first year post-transplant in patients who experienced
521 graft rejection (red), with these elevated levels persisting at follow-up. Vertical red bars indicate
522 individua graft rejection (red), with these elevated levels persisting at follow-up. Vertical red bars indicate
522 individual rejection events over time. B) Analysis of minimum creatinine levels before and after
523 sampling, along 522 individual rejection events over time. B) Analysis of minimum creatinine levels before and after
523 sampling, along with the time taken to reach the first. C) Gut microbial communities of the two
524 groups based on B 523 sampling, along with the time taken to reach the first. C) Gut microbial communities of the two
524 groups based on Bray-Curtis dissimilarity, demonstrate clear separation, with the rejection group
524 524 groups based on Bray-Curtis dissimilarity, demonstrate clear separation, with the rejection group
27 \sim 344 groups based on Bray-Curtis dissimilarity, demonstrate clear separation, with the rejection, groups group

525 526 (represent the centroids of the groups. D) Microbial diversity metrics, including number of detected
527 (OTUs, Shannon diversity, and Simpson evenness. E) Differences in microbial taxa between groups,
528 (highlightin 527 OTUs, Shannon diversity, and Simpson evenness. E) Differences in microbial taxa between groups,
528 highlighting a decrease in short-chain fatty acid (SCFA)-producing bacteria in the rejection group and
529 an enrichme 528 highlighting a decrease in short-chain fatty acid (SCFA)-producing bacteria in the rejection group and
529 an enrichment of genera commonly elevated in chronic kidney disease (CKD) and disease conditions.
530 Bacteria 529 an enrichment of genera commonly elevated in chronic kidney disease (CKD) and disease conditions.
530 Bacteria are shown in a phylogenetic tree where green lineages represent bacteria depleted and
531 pink bacteria enr 530 Bacteria are shown in a phylogenetic tree where green lineages represent bacteria depleted and
531 pink bacteria enriched in patients with kidney rejection F) Differential abundance analysis of
532 bacterial genera, wi pink bacteria enriched in patients with kidney rejection F) Differential abundance analysis of
bacterial genera, with significant changes identified between non-rejection and rejection groups.
Cliff's Delta values indicate bacterial genera, with significant changes identified between non-rejection and rejection groups.

533 Cliff's Delta values indicate the direction and extent of these differences. Blue dots show genera

534 increased in th Elift's Delta values indicate the direction and extent of these differences. Blue dots show genera
increased in the non-rejection group and red increased in the rejection group.
535 533 Cliff's Delta values indicate the direction and extent of these differences. Blue dots show genera
increased in the non-rejection group and red increased in the rejection group.
535 Fi<mark>gure 3. Fecal short-chain fatty a</mark>

535
535 Figure 3. Fecal short-chain fatty acid production potential is reduced bef
537 Figure 3. Fecal short-chain fatty acid production potential is reduced bef
537 Figure 9. Patients with available fecal samples prior to 536
537
538
538 Figure 3. Fecal short-chain fatty acid production potential is reduced before kidney ransplant

strategieve in the available fecal samples prior to kidney rejection (Rejection group) for

propensity score matched (1:2) to Figures with available fecal samples prior to kidney rejection (Rejection group).

Inference of functional data from taxonomic data using PICRUSt2 and mapping to pathways using

GOmixer. A) Clustering of kidney transplant Fropensity score matched (1:2) to patients matter matter, regearch (1:2) to pathways using
539 Inference of functional data from taxonomic data using PICRUSt2 and mapping to pathways using
540 GOmixer. A) Clustering of kid 540 GOmixer. A) Clustering of kidney transplant recipients based on the presence (red circles) or absence
541 (blue circles) of graft rejection, illustrating differences in microbiome-derived functional potential.
542 Squa 541 (blue circles) of graft rejection, illustrating differences in microbiome-derived functional potential.
542 Squares represent centroids. B) Functional pathways highlight an increase in proteolytic
543 fermentation and Squares represent centroids. B) Functional pathways highlight an increase in proteolytic
543 fermentation and reactive nitrogen and oxygen species production pathways in patients who
544 experienced graft rejection (red). Functional pathways in pathways in pathways in protesty.
543 Fermentation and reactive nitrogen and oxygen species production pathways in patients who
544 experienced graft rejection (red). Non-rejection samples show enhan experienced graft rejection (red). Non-rejection samples show enhanced pathways related to sugar

545 and polysaccharide metabolism, and mucus degradation (blue). C) Heatmap shows all 54 significant

546 GOmixer modules, w 545 and polysaccharide metabolism, and mucus degradation (blue). C) Heatmap shows all 54 significant
546 GOmixer modules, with pink indicating high predicted abundances and green representing low
547 abundances across the 546 GOmixer modules, with pink indicating high predicted abundances and green representing low
547 abundances across the 92 patients, divided into non-rejection and rejection. Blue dots denote
548 negative log2 fold change 547 abundances across the 92 patients, divided into non-rejection and rejection. Blue dots denote
548 negative log2 fold changes, indicating enhanced modules in non-rejection samples compared to negative log2 fold changes, indicating enhanced modules in non-rejection samples compared to
1987 application. Blue dots denotes the product of the 92 patients. Blue dots denotes do the 92 patients. The
28 548 negative log2 fold changes, indicating enhanced modules in non-rejection samples compared to

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.21.24307660;](https://doi.org/10.1101/2024.05.21.24307660) this version posted May 21, 2024. The copyright holder for this preprint

549 550 patients experiencing graft rejection.
551
552 Figure 4. Decreased abundance of short-chain fatty acid producing enzymes in the microbiome

551
552 Figure 4. Decreased abundance of s
553 before kidney transplant rejection. 552
553
554
554 1. But 4. Decreased abundance of short-chain fatty acid producing enzymes in the microbiome
553 **before kidney transplant rejection**. Patients with available fecal samples prior to kidney rejection
554 (Rejection group). A SES (Rejection group) for propensity score matched (1:2) to patients without kidney rejection (Non-
Rejection group). A) Bacterial nutrient metabolism leading to SCFA, specifically butyrate and
SES propionate, production. 558 While bcd was not significantly altered but and mmdA showed lower abundance in fecal samples 556 propionate, production. Key bacterial enzymes highlighted in red. B) Abundance of bacterial
557 enzymes for SCFA production were assessed by qPCR from fecal DNA and normalized to 16s content.
558 While bcd was not sign EST enzymes for SCFA production were assessed by qPCR from fecal DNA and normalized to 16s content.

558 While *bcd* was not significantly altered *but* and *mmdA* showed lower abundance in fecal samples

559 from patients 558 While *bcd* was not significantly altered *but* and *mmdA* showed lower abundance in fecal samples
559 from patients with subsequent kidney rejection compared to those without rejection.
560 559 While bcd was not significantly altered *but* and *mmdA* showed lower abundance in fecal samples
559 from patients with subsequent kidney rejection compared to those without rejection.
560 **Figure 5. Microbiome composi**

560
561 Figure 5. Microbiome composition normalizes post-kidney transplant rejection.
562 available fecal samples (sample 1) prior to kidney rejection (Rejection group) and san 561
562
563
564 Example 5. Microbiome composition normalizes post-kidney transplant refection. Patients with
available fecal samples (sample 1) prior to kidney rejection (Rejection group) and sample 2 90-1000
563 days post-rejection were 563 days post-rejection were analyzed. Propensity score matched patients without kidney rejection
564 (Non-Rejection group) with two comparable samples were included as controls. A) Principal
565 Coordinates Analysis (PCoA 564 (Non-Rejection group) with two comparable samples were included as controls. A) Principal
565 Coordinates Analysis (PCoA) of microbiome samples based on Bray-Curtis dissimilarity demonstrates
566 a shift in the microbi Coordinates Analysis (PCoA) of microbiome samples based on Bray-Curtis dissimilarity demonstrates
566 a shift in the microbiome composition of rejection patients (red to purple) towards the non-rejection
567 group (blue) o 566 a shift in the microbiome composition of rejection patients (red to purple) towards the non-rejection
567 group (blue) over time, suggesting a post-rejection stabilization. Squares represent centroids. B)
568 Microbial 567 group (blue) over time, suggesting a post-rejection stabilization. Squares represent centroids. B)
568 Microbial diversity measured by the number of detected OTU, Shannon diversity, and Simpson
569 evenness. C) Heatmap 568 Microbial diversity measured by the number of detected OTU, Shannon diversity, and Simpson
569 evenness. C) Heatmap comparison of genus-level alterations between pre- and post-rejection
570 samples reveals significant External diversion of genus-level alterations between pre- and post-rejection
1570 Samples reveals significant directional changes in microbial populations after a rejection event,
1571 contrasting with the stable profiles 570 samples reveals significant directional changes in microbial populations after a rejection event,
571 contrasting with the stable profiles observed in non-rejection controls. Pre-rejection comparison
572 taken from Fig 571 contrasting with the stable profiles observed in non-rejection controls. Pre-rejection comparison
572 taken from Figure 3F. Asterisks indicate significance levels: FDR < 0.1 * FDR < 0.01 ** FDR < 0.001 ***.
573 Confoun 572 taken from Figure 3F. Asterisks indicate significance levels: FDR < 0.1 * FDR < 0.01 ** FDR < 0.001 ***.
573 Confounded signals are shown as circles. Effect size is shown as Cliffs delta with pink enriched and
29 573 Confounded signals are shown as circles. Effect size is shown as Cliffs delta with pink enriched and
29 573 Conformation as circles. Effect size is shown as circles. Effect size is shown as 29

574

575 Blautia and Faecalibacterium, and disease-associated genera, Fusobacterium and Streptococcus.
576
577 Figure 6. Microbiome composition in kidney rejection partly mirrors CKD-related microbiome Blautia and Faecalibacterium, and disease-associated genera, Fusobacterium and Streptococcus.
576
577 **Figure 6. Microbiome composition in kidney rejection partly mirrors CKD-related microbional and Streptococcus**
578 **alt** 577
578
579
580 1. The C. Microbiome composition in Kuney rejection partly mirrors cKD-related microbiome

578 alterations. Correlation between CKD microbial signatures and kidney transplant rejection preceding

580 before kidney transpla signatures. A) Scatter plot indicating the correlation between the microbial signatures observed
before kidney transplant (KT) rejections and those seen in chronic kidney disease (CKD) patients,
581 suggesting shared alter 580 before kidney transplant (KT) rejections and those seen in chronic kidney disease (CKD) patients,
581 suggesting shared alterations. Dashed line indicates perfect overlap of effect sizes. B) Log
582 transformed rarefie 581 suggesting shared alterations. Dashed line indicates perfect overlap of effect sizes. B) Log
582 transformed rarefied abundance of key SCFA-producing genera (*Blautia* and *Faecalibacterium*) and
583 disease-associated 582 transformed rarefied abundance of key SCFA-producing genera (*Blautia* and *Faecalibacterium*) and
583 disease-associated genera (*Streptococcus* and *Fusobacterium*) across healthy controls (HC), CKD
584 patients, and disease-associated genera (*Streptococcus* and *Fusobacterium*) across healthy controls (HC), CKD
patients, and KT recipients preceding graft rejection or without graft rejection (propensity-score
585 matched). C) Abundanc disease-associated genera (Streptococcus and Fusobucterium) across healthy controls (HC), CKD
patients, and KT recipients preceding graft rejection or without graft rejection (propensity-score
585 matched). C) Abundance of 585 matched). C) Abundance of bacterial taxa involved in butyrate and propionate production between
586 HC and CKD patients, reflecting a decrease in these beneficial taxa in CKD. 586 HC and CKD patients, reflecting a decrease in these beneficial taxa in CKD. 586 HC and CKD patients, reflecting a decrease in these beneficial taxa in CKD.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.21.24307660;](https://doi.org/10.1101/2024.05.21.24307660) this version posted May 21, 2024. The copyright holder for this preprint

588 1. Web:
588 1. Web:
589 2017;389(100
590 2. Harih
591 *J Med*. Aug 1:
592 3. Coop
593 *Nephrol*. Mar 1. Webster Ac, Nagler Ev, Morton RE, Masson P. Chronic Ridney Bisease. Edite: Mar 25

589 2017;389(10075):1238-1252. doi:10.1016/S0140-6736(16)32064-5

2. Hariharan S, Israni AK, Danovitch G. Long-Term Survival after Kidne 2014,157(1):121-141. doi:10.1016/j.mmuni.2017.04.008

589 2. Hariharan S, Israni AK, Danovitch G. Long-Term Survival afte

591 *J Med.* Aug 19 2021;385(8):729-743. doi:10.1056/NEJMra2014530

592 3. Cooper JE. Evaluation an 2. Hariharan S, Israin AK, Danovitch G. Long-Term Survival after Kidney Transplantation. N Engl
591 J Med. Aug 19 2021;385(8):729-743. doi:10.1056/NEJMra2014530
592 8. Cooper JE. Evaluation and Treatment of Acute Rejection 591 J Med. Aug 19 2021,585(8):725 745. doi:10.1056/NEJMR2014535

592 3. Cooper JE. Evaluation and Treatment of Acute Rejection in

593 Mephrol. Mar 6 2020;15(3):430-438. doi:10.2215/CJN.11991019

4. Belkaid Y, Hand TW. Rol Society of the Evaluation and Treatment of Acute Rejection in Kidney Anografts. Clin J Am Society Rephrol. Mar 6 2020;15(3):430-438. doi:10.2215/CJN.11991019

4. Belkaid Y, Hand TW. Role of the microbiota in immunity and i Source Mennon. Mar 6 2020;15(3):430-438. doi:10.2215) CIN:11331013
594 4. Belkaid Y, Hand TW. Role of the microbiota in immunity and
595 2014;157(1):121-141. doi:10.1016/j.cell.2014.03.011
596 5. Belkaid Y, Harrison OJ. Ho 595 2014;157(1):121-141. doi:10.1016/j.cell.2014.03.011
596 5. Belkaid Y, Harrison OJ. Homeostatic Immunity and the Microbiota. Immunity. Apr 18
597 2017;46(4):562-576. doi:10.1016/j.immuni.2017.04.008
598 6. Behrens F, Ba 596 5. Belkaid Y, Harrison OJ. Homeostatic Immunity
597 2017;46(4):562-576. doi:10.1016/j.immuni.2017.04.0
598 6. Behrens F, Bartolomaeus H, Wilck N, Holle J. C
600 7. Schlender J, Behrens F, McParland V, et al. Ba
601 chi 596 5. Behkaid T, Harrison OJ. Homeostatic Immanity and the Microbiota. Immanity. Apr 18
597 2017;46(4):562-576. doi:10.1016/j.immuni.2017.04.008
598 6. Behrens F, Bartolomaeus H, Wilck N, Holle J. Gut-immune axis and card 598 6. Behrens F, Bartolomaeus H, Wilck N, Holle J. Gut
599 chronic kidney disease. *Clin Kidney J*. Jan 2024;17(1):sfad
600 7. Schlender J, Behrens F, McParland V, et al. Bacte
601 children with chronic kidney disease. *M* 599 chronic kidney disease. *Clin Kidney J. Jan 2024;17(1):sfad303. doi:10.1093/ckj/sfad303*
500 7. Schlender J, Behrens F, McParland V, et al. Bacterial metabolites and cardiovascular risk
501 children with chronic kidney Einome kidney disease. Clin Kidney J. Jan 2024;17(1): Stad303. doi:10.10937ekjj stad303

599 Chronic kidney disease. Mol Cell Pediatr. Oct 22 2021;8(1):17. doi:10.1186

602 O0126-8

8. Holle J, Bartolomaeus H, Lober U, et 601 children with chronic kidney disease. *Mol Cell Pediatr*. Oct 22 2021;8(1):17. doi:10.1186/s40348-02
602 00126-8
8. Holle J, Bartolomaeus H, Lober U, et al. Inflammation in Children with CKD Linked to Gut
604 Dysbiosis 602 children with chronic kidney disease. Moreen Fediatr. Oct 22 2021,0(1):17. doi:10.1180/s40340-021-
603 8. Holle J, Bartolomaeus H, Lober U, et al. Inflammation in Children with CKD Linked to Gut
604 Dysbiosis and Metab 003 8. H

004 Dysbiosis

005 doi:10.16

005 doi:10.11

007 regulate

008 doi:10.11

009 10. S

010 Renal Tra Example 10. Holle Implance Comparent Dec 2022;33(12):2259-2275.

605 doi:10.1681/ASN.2022030378

606 9. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids

606 9. Smith PM, Howitt MR, Bosand Metabolite Imbalance. J Am Joc Nephrol. Dec 2022, 33(12):2233) 2275.

doi:10.1681/ASN.2022030378

606 9. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chai

regulate colonic Treg cell homeo 606 9. Smith PM, Howitt MR,
607 regulate colonic Treg cell home
608 doi:10.1126/science.1241165
609 10. Swarte JC, Douwes RM
610 Renal Transplant Recipients. J (611 11. Lee JR, Magruder M, Zl
612 transplant recipients. Am regulate colonic Treg cell homeostasis. Science. Aug 2 2013;341(6145):569-573.
608 doi:10.1126/science.1241165
609 10. Swarte JC, Douwes RM, Hu S, et al. Characteristics and Dysbiosis of the Gut Microbiome in
610 Renal Tra Figure colonic Treg cerrifonessessis. Science. Aug 2 2013,541(6143):569-573.

doi:10.1126/science.1241165

609 10. Swarte JC, Douwes RM, Hu S, et al. Characteristics and Dysbiosis of the G

Renal Transplant Recipients. J C 609 10. Swarte JC, Douwes RM
610 Renal Transplant Recipients. J
611 11. Lee JR, Magruder M, Z
612 transplant recipients. Am J Tra
613 12. Fricke WF, Maddox C,
614 of renal transplantation. Am J
615 13. Swarte JC, Li Y, Hu For Renal Transplant Recipients. *J Clin Med*. Feb 1 2020;9(2)doi:10.3390/jcm9020386

11. Lee JR, Magruder M, Zhang L, et al. Gut microbiota dysbiosis and diarrhea in kidney

11. Lee JR, Magruder M, Zhang L, et al. Gut mic 611 11. Lee JR, Magruder M, Zhang L, et al. Gut microbiota dysbiosis and diarrhea
612 Feb 1 2020;9(2):488-500. doi:10.1111/ajt.1
613 12. Fricke WF, Maddox C, Song Y, Bromberg JS. Human microbiota characteriz
614 of renal t 612 transplant recipients. Am J Transplant. Feb 2019;19(2):488-500. doi:10.1111/ajt.14974
613 12. Fricke WF, Maddox C, Song Y, Bromberg JS. Human microbiota characterization in th
614 of renal transplantation. Am J Transp Final Figure 1.12 Transplant. Feb 2019;19(2):488-300: doi:10.1111/ajt.14974

12. Fricke WF, Maddox C, Song Y, Bromberg JS. Human microbiota characterization

614 of renal transplantation. Am J Transplant. Feb 2014;14(2):4 614 of renal transplantation. Am J Transplant. Feb 2014;14(2):416-427. doi:10.1111/ajt.12588
615 13. Swarte JC, Li Y, Hu S, et al. Gut microbiome dysbiosis is associated with increased mortality
616 after solid organ tran 615 13. Swarte JC, Li Y, Hu S, et al. Gut microbiome dysbiosis is associated with increased r
616 after solid organ transplantation. *Sci Transl Med*. Aug 31 2022;14(660):eabn7566.
617 doi:10.1126/scitranslmed.abn7566
618 For a first solid organ transplantation. *Sci Transl Med*. Aug 31 2022;14(660):eabn7566.

doi:10.1126/scitranslmed.abn7566

14. Lei YM, Chen L, Wang Y, et al. The composition of the microbiota modulates allograft

rejectio 617 diel solid organ transplantation. Scr Hunsi Med. Aug 31 2022,14(000):eabn7560
618 14. Lei YM, Chen L, Wang Y, et al. The composition of the microbiota modulate
619 rejection. J Clin Invest. Jul 1 2016;126(7):2736-2744. 18 14. Lei YM, Chen L, Wang Y, et a

619 rejection. *J Clin Invest*. Jul 1 2016;12

620 15. Sato Y, Yanagita M. Immunc

621 2019;15(10):625-640. doi:10.1038/s

622 16. Wilck N, Matus MG, Kearne

623 and disease. *Nature*. France Care in the microsoft Care in the microsoft Care in the microsoft Care in Sato Y, Yanagita M. Immunology of the ageing kidney. Nature reviews Nephrology. Oc

620 15. Sato Y, Yanagita M. Immunology of the ageing kidn 620 15. Sato Y, Yanagita M. Immunology of the ageing kidney. Nature revies
621 2019;15(10):625-640. doi:10.1038/s41581-019-0185-9
622 16. Wilck N, Matus MG, Kearney SM, et al. Salt-responsive gut commer
623 and disease. Na 621 15. Sato Y, Yanagita M. Immunology of the ageing kidney. Nature reviews Nephrology. Oct 2019;15(10):625-640. doi:10.1038/s41581-019-0185-9
622 16. Wilck N, Matus MG, Kearney SM, et al. Salt-responsive gut commensal mod Example 1221, 10018 2019

622 16. Wilck N, Matus MG, Kearney SM, et al. Salt-resp

623 and disease. Nature. Nov 30 2017;551(7682):585-589.

624 17. Bartolomaeus H, Balogh A, Yakoub M, et al. Shc

625 Hypertensive Cardiovas and disease. *Nature*. Nov 30 2017;551(7682):585-589. doi:10.1038/nature24628
624 17. Bartolomaeus H, Balogh A, Yakoub M, et al. Short-Chain Fatty Acid Propionate Protects From
625 Hypertensive Cardiovascular Damage. *Circ* 623 and disease. Nuture. Nov 30 2017;351(7062):365-365. doi:10.1036/nature24026
624 17. Bartolomaeus H, Balogh A, Yakoub M, et al. Short-Chain Fatty Acid Propic
625 Hypertensive Cardiovascular Damage. *Circulation*. Mar 12 Example 17. Bartolomaeus Circulation. Mar 12 2019;139(11):1407-1421.

625 Hypertensive Cardiovascular Damage. Circulation. Mar 12 2019;139(11):1407-1421.

627 18. Wu H, Singer J, Kwan TK, et al. Gut Microbial Metabolites I 625 Hypertensive Cardiovascular Damage. Circulation: Mar 12 2019,139(11):1407-1421.
626 doi:10.1161/CIRCULATIONAHA.118.036652
627 18. Wu H, Singer J, Kwan TK, et al. Gut Microbial Metabolites Induce Donor-Spec
628 Kidney A 18. Wu H, Singer J, Kwan TK, et al. Gut N
628 Kidney Allografts through Induction of T Reg
629 *Nephrol.* Jun 1 2020;doi:10.1681/ASN.20190
630 19. Singer J, Li YJ, Ying T, et al. Protocol 1
631 controlled trial of dietary Kidney Allografts through Induction of T Regulatory Cells by Short-Chain Fatty Acids. J Am Soc
629 Nephrol. Jun 1 2020;doi:10.1681/ASN.2019080852
630 19. Singer J, Li YJ, Ying T, et al. Protocol for a pilot single-centre, Richley Allografts through Induction of T Regulatory Cells by Short-Chain Fatty Acids. J Am Soc Nephrol. Jun 1 2020;doi:10.1681/ASN.2019080852
630 19. Singer J, Li YJ, Ying T, et al. Protocol for a pilot single-centre, par 630 19. Singer J, Li YJ, Ying T, et al. Protocol for a pil
631 controlled trial of dietary inulin to improve gut heal
632 study. *BMJ Open*. 2021;11(4)
633 20. Sawitzki B, Harden PN, Reinke P, et al. Regu
634 ONE Study): a 631 controlled trial of dietary inulin to improve gut health in solid organ transplantation: the DIGES study. *BMJ Open.* 2021;11(4)
632 study. *BMJ Open.* 2021;11(4)
633 20. Sawitzki B, Harden PN, Reinke P, et al. Regulat 632 study. *BMJ Open.* 2021;11(4)
632 study. *BMJ Open.* 2021;11(4)
633 20. Sawitzki B, Harden PN, Reinke P, et al. Regulatory cell therapy in kidney transplantation (ONE Study): a harmonised design and analysis of seven n 632 study. BMJ Open. 2021;11(4)
633 20. Sawitzki B, Harden PN
634 ONE Study): a harmonised de
635 trials. *Lancet*. May 23 2020;39 ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A

trials. *Lancet*. May 23 2020;395(10237):1627-1639. doi:10.1016/S0140-6736(20)30167-7

finals. *Lancet*. May 23 2020;395(10237): 635 trials. *Lancet*. May 23 2020;395(10237):1627-1639. doi:10.1016/S0140-6736(20)30167-7
trials. *Lancet*. May 23 2020;395(10237):1627-1639. doi:10.1016/S0140-6736(20)30167-7 635 trials. Lancet. May 23 2020;395(10237):1627-1639. doi:10.1016/S0140-6736(20)30167-7

636 $21.$ infection research (DZIF Tx-Cohort): study design and baseline characteristics. *Eur J Epidemiol.* Feb

638 2021;36(2):233-241. doi:10.1007/s10654-020-00715-3

639 22. Deutsche Stiftung Organtransplantation (German Organ P 638 2021;36(2):233-241. doi:10.1007/s10654-020-00715-3
638 2021;36(2):233-241. doi:10.1007/s10654-020-00715-3
640 *Nierentransplantation: Grafiken zum Tätigkeitsbericht 2022 nach* § 11 Abs. 5 TPG. 2022.
641 23. Kasiske BL, 22. Deutsche Stiftung Organtransplantation (Germonton Microphentation: Grafiken zum Tätigkeitsbericht 2
23. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO
22 kidney transplant recipients: a summary. *Kidney Int*. Fel
24. H Deutsche Stiftung Organtransplantation (German Organ Procurement Organization). 640 *Nierentransplantatie*
640 *Nierentransplantatie*
642 kidney transplant re
643 doi:10.1038/ki.2009
644 24. Ho DE, Imai
645 Model Dependence
646 doi:10.1093/pan/m_l ung Organtransplanta on (German Organ Procurement Organiza 641 23. Kasiske BL, 642 kidney transplant re
643 doi:10.1038/ki.2009
644 24. Ho DE, Imai
645 Model Dependence
646 doi:10.1093/pan/m
647 25. Loupy A, Ha
648 and clarification of (gkeitsbericht 2022 nach § 11 Abs. 5 TPG. 2022.
R, et al. KDIGO clinical practice guideline for the
Kidney Int. Feb 2010;77(4):299-311.
Matching as Nonparametric Preprocessing for F
Inference. Political Analysis. 2007;15(3) Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of Example 12. Kidney transplant recipients: a summary. Kidney Int. Feb 2010;77(4):299-311.

642 idi:10.1038/ki.2009.377

644 24. Ho DE, Imai K, King G, Stuart EA. Matching as Nonparametric Preprocessing for Reducing

645 Mod 642 kidney transplant recipients: a summary. Kidney *Int.* Feb 2010,77(4):299-311.
643 doi:10.1038/ki.2009.377
644 24. Ho DE, Imai K, King G, Stuart EA. Matching as Nonparametric Preproce
645 Model Dependence in Parametric 644 24. Ho DE, Imai K, Kir
645 Model Dependence in Pa
646 doi:10.1093/pan/mpl013
647 25. Loupy A, Haas M,
648 and clarification of criteri
649 2020;20(9):2318-2331. do
650 26. Ren Z, Fan Y, Li A,
651 *Adv Sci (Weinh)*. Oct Model Dependence in Parametric Causal Inference. *Political Analysis*. 2007;15(3):199-236.
646 doi:10.1093/pan/mpl013
647 25. Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): Updates or
648 and Model Dependence in Franchine Causar interence. Prometri Analysis. 2007;13(3):139-230.

doi:10.1093/pan/mpl013

25. Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): Upd.

and clarification of c 647 25. Loupy A, Haas M,
648 and clarification of criteria
649 2020;20(9):2318-2331. do
650 26. Ren Z, Fan Y, Li A,
651 *Adv Sci (Weinh)*. Oct 2020
652 27. Lahti L, Sudarshan
653 28. McMurdie PJ, Hol
654 Graphics of Microb and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. Sep

648 and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. Sep

650 26. Ren Z, Fan Y, Li and clarification of citeration 1 cell- and antibody-mediated rejection. Am J Transplant. Sep-

2020;20(9):2318-2331. doi:10.1111/ajt.15898

26. Ren Z, Fan Y, Li A, et al. Alterations of the Human Gut Microbiome in Chronic 850 26. Ren Z, Fan Y, Li A, et al. Alterations of t
651 *Adv Sci (Weinh)*. Oct 2020;7(20):2001936. doi:1
652 27. Lahti L, Sudarshan S. microbiome R pa
653 28. McMurdie PJ, Holmes S. phyloseq: An I
654 Graphics of Microbiom Adv Sci (Weinh). Oct 2020;7(20):2001936. doi:10.1002/advs.202001936
651 Adv Sci (Weinh). Oct 2020;7(20):2001936. doi:10.1002/advs.202001936
652 27. Lahti L, Sudarshan S. microbiome R package. http://microbiome.github.io
65 652 27. Lahti L, Sudarshan S. microbiome R package. http://microbiome.
653 28. McMurdie PJ, Holmes S. phyloseq: An R Package for Reproducibl
654 Graphics of Microbiome Census Data. *PLOS ONE*. 2013;8(4):e61217.
655 doi:10. 28. McMurdie PJ, Holmes S. phyloseq: An R Package for Reproducible Interact
654 Graphics of Microbiome Census Data. *PLOS ONE*. 2013;8(4):e61217.
655 doi:10.1371/journal.pone.0061217
656 29. Oksanen J, Blanchet FG, Kindt R 654 Graphics of Microbiome Census Data. *PLOS ONE*. 2013;8(4):e61217.
655 doi:10.1371/journal.pone.0061217
656 29. Oksanen J, Blanchet FG, Kindt R, et al. Community ecology package. *R package version*.
657 2013;2(0):321-3 doi:10.1371/journal.pone.0061217
655 doi:10.1371/journal.pone.0061217
656 29. Oksanen J, Blanchet FG, Kindt R, et al. Community ecology p:
657 2013;2(0):321-326.
658 30. Forslund SK, Chakaroun R, Zimmermann-Kogadeeva M, et 1656 29. Oksanen J, Blanchet FG, Kino
657 2013;2(0):321-326.
658 30. Forslund SK, Chakaroun R, Z
669 dose-dependent drug-microbiome a
660 doi:10.1038/s41586-021-04177-9
661 31. Chen C-Y, Liber U, Forslund
662 analysis of h Example 1, Blanchet FG, Kindt R, et al. Community ecology package. R package version.

2013;2(0):321-326.

30. Forslund SK, Chakaroun R, Zimmermann-Kogadeeva M, et al. Combinatorial, additive ar

dose-dependent drug-microb 658 30. Forslund SK
659 dose-dependent dru
660 doi:10.1038/s41586
661 31. Chen C-Y, LE
662 analysis of high-dim
663 32. Douglas GM
664 *Nature Biotechnolo*g
665 33. Darzi Y, Falc dose-dependent drug-microbiome associations. *Nature*. Dec 2021;600(7889):500-505.
660 doi:10.1038/s41586-021-04177-9
661 31. Chen C-Y, Liber U, Forslund SK. LongDat: an R package for covariate-sensitive longitudinal
862 a dose dependent drug-microbiome associations. Nature. Dec 2021,000(7089):500-505.

doi:10.1038/s41586-021-04177-9

661 31. Chen C-Y, LDDer U, Forslund SK. LongDat: an R package for covariate-sensitive lo

analysis of high-d 661 31. Chen C-Y, L**Der U, Forslun**
662 analysis of high-dimensional data.
663 32. Douglas GM, Maffei VJ, Za
664 *Nature Biotechnology*. 2020/06/01
665 33. Darzi Y, Falony G, Vieira-Si
666 *ISME J*. May 2016;10(5):1025-102 analysis of high-dimensional data. *Bioinformatics Advances*. 2023;doi:10.1093/bioadv/vbad063

563 32. Douglas GM, Maffei VJ, Zaneveld JR, et al. PICRUSt2 for prediction of metagenome function

564 *Nature Biotechnology*. analysis of high-dimensional data. *Biomformatics Advances. 2023*,doi:10.1093/bioadv/vbad003

32. Douglas GM, Maffei VJ, Zaneveld JR, et al. PICRUSt2 for prediction of metagenome funct
 Nature Biotechnology. 2020/06/01 2 Mature Biotechnology. 2020/06/01 2020;38(6):685-688. doi:10.1038/s41587-020-0548-6

565 33. Darzi Y, Falony G, Vieira-Silva S, Raes J. Towards biome-specific analysis of meta-omics data.

566 *ISME J*. May 2016;10(5):1025-Mature Biotechnology. 2020/06/01 2020,30(0):005-000. doi:10:10306/341507-020-0548-0
666 33. Darzi Y, Falony G, Vieira-Silva S, Raes J. Towards biome-specific analysis of meta-o
666 *ISME J*. May 2016;10(5):1025-1028. doi:1 15 SME J. May 2016;10(5):1025-1028. doi:10.1038/ismej.2015.188

666 3 34. Notting F, Pirovano W, Sybesma W, Kort R. The butyrate-producing and spore-forming

bacterial genus Coprococcus as a potential biomarker for neurolo 667 34. Notting F, Pirovano W, Sybesma W, Kort R. The butyrate-
668 34. Notting F, Pirovano W, Sybesma W, Kort R. The butyrate-
668 2023;4:e16. e16. doi:10.1017/gmb.2023.14
670 35. Zhang J, Song L, Wang Y, et al. Beneficia bacterial genus Coprococcus as a potential biomarker for neurological disorders. *Gut Microbior*

2023;4:e16. e16. doi:10.1017/gmb.2023.14

570 35. Zhang J, Song L, Wang Y, et al. Beneficial effect of butyrate-producing La Bacterial genus coprococcus as a potential biomarker for neurological disorders. Out Microbiome.

2023;4:e16. e16. doi:10.1017/gmb.2023.14

570 35. Zhang J, Song L, Wang Y, et al. Beneficial effect of butyrate-producing La 670 35. Zhang J, Song L, Wang Y, et al. Benef
671 stress-induced visceral hypersensitivity in ra
672 doi:10.1111/jgh.14536
673 36. Kasahara K, Krautkramer KA, Org E, diet modulate atherogenesis in a murine mo
675 doi:10.10 stress-induced visceral hypersensitivity in rats. *J Gastroenterol Hepatol*. Aug 2019;34(8):1368-1376
671 stress-induced visceral hypersensitivity in rats. *J Gastroenterol Hepatol*. Aug 2019;34(8):1368-1376
673 36. Kasaha 671 stress-induced visceral hypersensitivity in rats. J Gustroemeror rieputol. Aug 2015, 34(6): 1306-1376.
673 36. Kasahara K, Krautkramer KA, Org E, et al. Interactions between Roseburia intestinalis and
674 diet modulate 673 36. Kasahara K, Kra
674 diet modulate atheroge
675 doi:10.1038/s41564-01
676 37. Lenoir M, Martí
677 Faecalibacterium praus
678 2020;12(1):1-16. doi:10
679 38. Reichardt N, Du
680 propionate production 674 diet modulate atherogenesis in a murine model. Nat Microbiol. Dec 2018;3(12):1461-1471.
675 doi:10.1038/s41564-018-0272-x
676 37. Lenoir M, Martín R, Torres-Maravilla E, et al. Butyrate mediates anti-inflammatory effe diet modulate atherogenesis in a multie model. *Nat Microbiol.* Dec 2018;3(12):1401-1471.
675 doi:10.1038/s41564-018-0272-x
676 37. Lenoir M, Martín R, Torres-Maravilla E, et al. Butyrate mediates anti-inflammatory e
677 F 676 37. Lenoir M, Martín R, Torre
677 Faecalibacterium prausnitzii in in
678 2020;12(1):1-16. doi:10.1080/19
679 38. Reichardt N, Duncan SH,
680 propionate production within the
681 doi:10.1038/ismej.2014.14
682 39. Sayols Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3. *Gut Microbes*. Nov 9

2020;12(1):1-16. doi:10.1080/19490976.2020.1826748

38. Reichardt N, Duncan SH, Young P, et al. Phylogenetic distribution of Faced Bacterium prausing in intestinal epithelial cells through Dact3. Out Microbes. Nov 9

2020;12(1):1-16. doi:10.1080/19490976.2020.1826748

38. Reichardt N, Duncan SH, Young P, et al. Phylogenetic distribution of three 879 38. Reichardt N, Duncan SH, Young P, et al. Phyloge
680 propionate production within the human gut microbiota
681 doi:10.1038/ismej.2014.14
682 39. Sayols-Baixeras S, Dekkers KF, Baldanzi G, et al.
683 Is Linked to Sub 680 propionate production within the human gut microbiota. *ISME J.* Jun 2014;8(6):1323-1335.
681 doi:10.1038/ismej.2014.14
682 Sayols-Baixeras S, Dekkers KF, Baldanzi G, et al. Streptococcus Species Abundance in the
683 681 doi:10.1038/ismej.2014.14
682 doi:10.1038/ismej.2014.14
682 Sayols-Baixeras S, Dekkers KF, Baldanzi G, et al. Streptococcus Species Abundance in
683 Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participant 682 39. Sayols-Baixeras S, D
683 Is Linked to Subclinical Cord
684 *Circulation*. 2023;148(6):45
685 40. Gupta VK, Kim M, B
686 microbiome profiling. Nat C 683 Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participants From the SCAPIS Cohort.
684 *Circulation*. 2023;148(6):459-472. doi:doi:10.1161/CIRCULATIONAHA.123.063914
685 40. Gupta VK, Kim M, Bakshi U, et al. 684 Circulation. 2023;148(6):459-472. doi:doi:10.1161/CIRCULATIONAHA.123.063914
685 40. Gupta VK, Kim M, Bakshi U, et al. A predictive index for health status using species-leve
microbiome profiling. *Nat Commun*. Sep 15 2 $Circulation. 2023,148(6).39,472. 601.601.101101/CHCOLEATIONATIA.123.003314
\n685 40. Gupta VK, Kim M, Bakshi U, et al. A predictive index for health status using
\nmicrobiome profiling. *Nat Commun.* Sep 15 2020;11(1):4635. doi:10.1038/s41467$ 686 microbiome profiling. *Nat Commun.* Sep 15 2020;11(1):4635. doi:10.1038/s41467-020-18476-8 686 microbiome profiling. Nat Commun. Sep 15 2020;11(1):4635. doi:10.1038/s41467-020-18476-8

687 41. For Porphyromonas gingivalis induces cardiovascular dysfunction. Can J Physiol Pharmacol

1689 2023;101(8):413-424. doi:10.1139/cjpp-2022-0392

1690 42. Vieira-Silva S, Falony G, Darzi Y, et al. Species-function relationsh Forphyromonas gingivalis induces cardiovascular dystanction. Can J Physiol Pharmacol. Aug 1

2023;101(8):413-424. doi:10.1139/cjpp-2022-0392

42. Vieira-Silva S, Falony G, Darzi Y, et al. Species-function relationships sha 42. Vieira-Silva S, Falony G, Darzi Y, et al. Specie

691 properties of the human gut microbiome. Nat Micro

692 doi:10.1038/nmicrobiol.2016.88

693 43. Wang X, Yang S, Li S, et al. Aberrant gut mic

694 renal failure in h France of the human gut microbiome. *Nat Microbiol.* Jun 13 2016;1(8):16088.

doi:10.1038/nmicrobiol.2016.88

43. Wang X, Yang S, Li S, et al. Aberrant gut microbiota alters host metabolome and impa

1976 renal failure in 692 doi:10.1038/nmicrobiol.2016.88
693 doi:10.1038/nmicrobiol.2016.88
693 43. Wang X, Yang S, Li S, et al. Aberrant gut microbiota alters host metabolom
694 renal failure in humans and rodents. *Gut*. Dec 2020;69(12):2131-For the Wang X, Yang S, Li S, et a
693 doi:10.1038.11 minutas and roder
695 319766
696 doi:10.1681/ASN.2014111063
698 doi:10.1681/ASN.2014111063
699 45. Opdebeeck B, Maudsley !
700 Vascular Calcification and Associa Figure 13. The 2020, $69(12):2131-2142$. doi:10.1136/gutjnl-2019-

695 44. Stubbs JR, House JA, Ocque AJ, et al. Serum Trimethylamine-N-Oxide is Elevated in CKD a

697 Correlates with Coronary Atherosclerosis Burden. *J Am* Ferial ration in Hamilans and rodents. Gut. Dec 2020,05(12):2151-2142. doi:10.1130/gutjnl-2015
695 319766
696 44. Stubbs JR, House JA, Ocque AJ, et al. Serum Trimethylamine-N-Oxide is Elevated in CKD:
697 Correlates with C 696 44.
697 Correlat
698 doi:10.1
699 45.
700 Vascular
701 2019;30
702 46.
703 progress Correlates with Coronary Atherosclerosis Burden. J Am Soc Nephrol. Jan 2016;27(1):305-313.
698 45. Opdebeeck B, Maudsley S, Azmi A, et al. Indoxyl Sulfate and p-Cresyl Sulfate Promote
700 Vascular Calcification and Associa Correlates with Coronary Atherosclerosis Burden. J Am Soc Nephrol. Jan 2010,27(1):305-313.

698 doi:10.1681/ASN.2014111063

45. Opdebeeck B, Maudsley S, Azmi A, et al. Indoxyl Sulfate and p-Cresyl Sulfate Promote

700 vasc 45. Opdebeeck B, Maudsle

700 Vascular Calcification and Asso

701 2019;30(5):751-766. doi:10.16

702 46. Holle J, Kirchner M, Ok

703 progression of chronic kidney c

704 doi:10.1371/journal.pone.0240

705 47. Gacesa R, K Vascular Calcification and Associate with Glucose Intolerance. J Am Soc Nephrol. May

2019;30(5):751-766. doi:10.1681/ASN.2018060609

702 46. Holle J, Kirchner M, Okun J, et al. Serum indoxyl sulfate concentrations associ 701 2019;30(5):751-766. doi:10.1681/ASN.2018060609
702 46. Holle J, Kirchner M, Okun J, et al. Serum indoxyl sulfate concentrations associa
703 progression of chronic kidney disease in children. *PLoS One*. 2020;15(10):e02 202 2012

702 46. Holle J, Kirchner M, Okun J, et al. Serum ind

703 progression of chronic kidney disease in children. *PL*

704 doi:10.1371/journal.pone.0240446

705 47. Gacesa R, Kurilshikov A, Vich Vila A, et al. En

7 progression of chronic kidney disease in children. *PLoS One*. 2020;15(10):e0240446.

1704 doi:10.1371/journal.pone.0240446

1705 47. Gacesa R, Kurilshikov A, Vich Vila A, et al. Environmental factors shaping the gut micro From Friedmann of chronic kidney disease in children. PLOS One. 2020,15(10):e0240446.

705 47. Gacesa R, Kurilshikov A, Vich Vila A, et al. Environmental factors shaping the

in a Dutch population. *Nature.* 2022/04/01 202 705 47. Gacesa R, Kurilshikov A, Vicl
706 in a Dutch population. Nature. 2022
707 04567-7
708 48. Avery EG, Bartolomaeus H,
709 inflammation and hypertensive org;
710 49. Sanna S, van Zuydam NR, M
711 short-chain fatty aci 1706 in a Dutch population. *Nature.* 2022/04/01 2022;604(7907):732-739. doi:10.1038/s41586-022-707

1707 04567-7

1707 04567-7

1708 48. Avery EG, Bartolomaeus H, Rauch A, et al. Quantifying the impact of gut microbiota o To a Dutch population. Nutrie. 2022/04/01 2022;004(7507):732-755. doi:10.1038/s41586-022-707 04567-7

708 48. Avery EG, Bartolomaeus H, Rauch A, et al. Quantifying the impact of gut microbiota on

inflammation and hyperten 107 108

10709 inflamma

10710 109 5

111 short-cha

112 doi:10.10

113 50 k

114 tolerance

115 doi:10.10 inflammation and hypertensive organ damage. Cardiovasc Res. Jul 29 2022;doi:10.1093/cvr/cva

710 49. Sanna S, van Zuydam NR, Mahajan A, et al. Causal relationships among the gut microbio

58. Short-chain fatty acids and me Frammation and hypertensive organ damage. Cardiovase Res. 3af 29 2022;doi:10.1093/cvr/cvac121

10 49. Sanna S, van Zuydam NR, Mahajan A, et al. Causal relationships among the gut microbiome,

11 short-chain fatty acids and 9211 short-chain fatty acids and metabolic diseases. Nat Genet. Apr 2019;51(4):600-605.

712 doi:10.1038/s41588-019-0350-x

713 50. Kim CH. Complex regulatory effects of gut microbial short-chain fatty acids on immune

714 711 short-chain fatty acids and inctabolic diseases. Wat denet. Apr 2019,91(4):000-005.
712 doi:10.1038/s41588-019-0350-x
713 50. Kim CH. Complex regulatory effects of gut microbial short-chain fatty acids contract to ther 713 50. Kim CH. Complex regulat

714 tolerance and autoimmunity. Cel

715 doi:10.1038/s41423-023-00987-

716 51. Langille MGI, Zaneveld J,

717 communities using 16S rRNA mai

718 2013;31(9):814-821. doi:10.1038

719 52. A 714 tolerance and autoimmunity. *Cellular & Molecular Immunology*. 2023/04/01 2023;20(4):341-35

715 doi:10.1038/s41423-023-00987-1

716 51. Langille MGI, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of 714 Colciance and autominium ty. Cendiar & Molecular Immanology: 2023/04/01 2023,20(4):341 350.

716 51. Langille MGI, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial

717 communities using 16S 716 51. Langille MGI, Zaneveld J, C
717 communities using 16S rRNA mark
718 2013;31(9):814-821. doi:10.1038/
719 52. Arpaia N, Campbell C, Fan
720 peripheral regulatory T-cell genera
721 doi:10.1038/nature12726
722 53. Wu 717 communities using 16S rRNA marker gene sequences. *Nature Biotechnology*. 2013/09/01
718 2013;31(9):814-821. doi:10.1038/nbt.2676
719 52. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria p 2013;31(9):814-821. doi:10.1038/nbt.2676
719 S2. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria p
720 peripheral regulatory T-cell generation. Nature. Dec 19 2013;504(7480):451-455.
721 doi: 52. Arpaia N, Campbell C, Fan X, et al. N

720 peripheral regulatory T-cell generation. Nat

721 doi:10.1038/nature12726

722 53. Wu H, Singer J, Kwan TK, et al. Gut I

723 Kidney Allografts through Induction of T Reg

724 peripheral regulatory T-cell generation. Nature. Dec 19 2013;504(7480):451-455.

721 doi:10.1038/nature12726

722 53. Wu H, Singer J, Kwan TK, et al. Gut Microbial Metabolites Induce Donor-Specific Tolerance

723 Kidney Al Peripheral regulatory T-cell generation. Nature. Dec 15 2015,304(7400):451-455.

721 doi:10.1038/nature12726

722 53. Wu H, Singer J, Kwan TK, et al. Gut Microbial Metabolites Induce Donor-S

723 Kidney Allografts through Framework Hubsin Chapter 1, Kw

722 53. Wu H, Singer J, Kw

723 Kidney Allografts through

724 *American Society of Nephr*

725 54. Rangaswami J, Ma

726 transplant recipient: epide

727 *Transplantation*. 2019;34(!

728 5 The Microsofter Microsofter Cells by Short-Chain Fatty Acids. Journal of the

2723 Kidney Allografts through Induction of T Regulatory Cells by Short-Chain Fatty Acids. Journal of the

274 American Society of Nephrology. 2 France Allow Allograms through Induction of Thegulatory Cells by Short-Chain Fatty Acids. Journal by the

724 American Society of Nephrology. 2020;31(7)

725 54. Rangaswami J, Mathew RO, Parasuraman R, et al. Cardiovascula 725 54. Rangaswami J, Mathew RO, Parasura
726 transplant recipient: epidemiology, diagnosis
727 Transplantation. 2019;34(5):760-773. doi:10
728 55. Lee JR, Muthukumar T, Dadhania D, eomplications after kidney transplantat Transplant recipient: epidemiology, diagnosis and management strategies. Nephrology Dialysis

Transplantation. 2019;34(5):760-773. doi:10.1093/ndt/gfz053

55. Lee JR, Muthukumar T, Dadhania D, et al. Gut microbial communit Transplant recipient: epidemiology, diagnosis and management strategies. Nephrology Diarysis

727 Transplantation. 2019;34(5):760-773. doi:10.1093/ndt/gfz053

728 55. Lee JR, Muthukumar T, Dadhania D, et al. Gut microbial 727 Transplantation. 2015,34(3):760-773. doi:10.10937/idt/gr2053
728 55. Lee JR, Muthukumar T, Dadhania D, et al. Gut microbia
730 705. doi:10.1097/tp.0000000000000370
731 56. Wang J, Li X, Wu X, et al. Gut microbiota alte 729 complications after kidney transplantation: a pilot study. Transplantation. Oct 15 2014;98
730 705. doi:10.1097/tp.000000000000370
731 56. Wang J, Li X, Wu X, et al. Gut microbiota alterations associated with antibody-729 complications after kidney transplantation: a pilot study. Transplantation: Oct 15 2014;30(7):037
730 705. doi:10.1097/tp.000000000000370
731 56. Wang J, Li X, Wu X, et al. Gut microbiota alterations associated with a 731 56. Wang J, Li X, Wu X, et al. Gut microsomology experiences doi:10.1007/s00253-020-11069-x
733 doi:10.1007/s00253-020-11069-x
734 732 rejection after kidney transplantation. Appl Microbiol Biotechnol. Mar 2021;105(6):2473-2484.
doi:10.1007/s00253-020-11069-x
734 732 rejection after kidney transplantation. Appl Microbiol Biotechnol. Mar 2021;105(6):2473-2464.
doi:10.1007/s00253-020-11069-x
734 734
734
1007

 $1400.0 \frac{2}{5}$

2010.0

0.333

0.500

ჟ

 $\mathbf B$

 $\mathbf C$